

Curriculum Vitae

PROFESSOR CHRISTINE ANN LEE
MA MD DSc(Med) FRCP FRCPATH FRCOG *ad eundem*

EMERITUS PROFESSOR OF HAEMOPHILIA
University College London

E-mail: Profcalee@GRO-C

09 June 2020

CONTENTS

Personal Details	Page 3
Prizes & Awards	4
Appointments	5
Research Grants	6
Peer Reviewed	6
Katharine Dormandy Trust / Commercial Sponsorship	7
Committees	9
Local / Regional / National / International	
Workshops	
Societies / Journals	1
Publications	11
Thesis / Scientific Papers	11
Books / Chapters in books	30
Review Articles	32
Letters	36
Postgraduate Students Supervised	39
Lectures	40
TOTAL PAGES	48

PERSONAL DETAILS

NAME : Christine A Lee
ADDRESS :

GRO-C

TELEPHONE :

GRO-C

DATE AND PLACE OF BIRTH :

GRO-C

GRO-C

Middlesex
FAMILY : Married to Professor Roy Pounder
Two sons - born 1976 and 1978

EDUCATION

1954 - 1962 Tiffin Girls School, Kingston, Surrey.
1962 - 1966 Somerville College, Oxford.
1966 - 1969 University of Oxford Medical School.

QUALIFICATIONS

BA (First Class Honours, Animal Physiology)	Oxford	1966
MA	Oxford	1969
BM BCh	Oxford	1969
MRCP	United Kingdom	1972
Accreditation in Haematology, JCHMT		1981
MRCPPath	London	1982
MD	London	1989
DSc (Med)	London	1996
FRCP	London	1990
FRCPPath	London	1994
FRCOG <i>ad eundem</i>	London	2010
BA (Honours) English Literature, First Class	Open University	2014

PRIZES AND AWARDS

1960 - 1961	Head Girl, Tiffin Girls School, Kingston-upon-Thames.
1965	Kirkaldy Prize in Natural Sciences, Somerville College, Oxford.
1966 - 1969	Clinical Scholarship, University of Oxford Medical School.
1967	Raddcliffe Prize in Pathology, University of Oxford Medical School.
1967 - 1968	Nuffield Travelling Scholarship, Christian Medical College, Vellore, South India.
1989	MD, University of London.
1992	Prix International de l'Association des Hemophiles awarded to Docteur PBA Kernoff and Docteur Christine A Lee.
1996	DSc (Med), University of London – awarded for a consistent contribution to the understanding of transfusion transmitted disease in the field of haemophilia.
1997	Personal Chair – Professor of Haemophilia, University College London
1999	Alfred Whole Time Medical Specialist Visiting Professorship, Alfred Hospital, Melbourne, Australia.
1999	Arosenius Lecture, the Arosenius Fund, Stockholm, Sweden.
2001	Clyde B McAuley Award (Alpha Award) 'Valuable contributions to the field of bleeding disorders in women'
2008	Fitzpatrick Lecture Royal College of Physicians ' <i>The best of times, the worst of times: a story of haemophilia.</i> '
2010	FRCOG <i>ad eundem</i> – awarded for work in the field of inherited bleeding disorders in women
2012	World Federation of Hemophilia International Lifetime Achievement Award, awarded for only the second time in the 50-year history of WFH, for furthering the mission and goals of the WFH throughout my career, and for a significant part of my life.

APPOINTMENTS

Jan 1962 - Oct 1962	Laboratory Technician: Dr D L Mollin, Department of Haematology, Royal Postgraduate Medical School, London.
July 1966 - Oct 1966	Postgraduate Research Assistant, Institute for Haematology under direction of Dr Fliedner, University Clinic, Freiburg, West Germany.
Aug 1969 - Jan 1970	HS to Mr AS Till, Radcliffe Infirmary, Oxford.
Feb 1970 - July 1970	HP to Dr JGG Ledingham and Dr G de J Lee, Radcliffe Infirmary, Oxford.
Aug 1970 - Jan 1971	SHO to Dr DK Peters (Renal Medicine), Hammersmith Hospital and Royal Postgraduate Medical School, London.
Feb 1971 - July 1971	SHO to Professor WB Matthews, Dr JS Spalding and Dr C Whitty (Neurology), United Oxford Hospitals.
Aug 1971	Admitting Doctor, Government General Hospital, Zaria, Nigeria.
Oct 1971 - Mar 1972	SHO to Professor JG Scadding, Dr KM Citron and Dr JR Bignall (Chest Medicine), Brompton Hospital, London.
April 1972 - Sept 1972	SHO to Dr JF Moorhead (Renal Medicine and Dialysis Unit), Royal Free Hospital, London.
Nov 1972 - June 1973	Research Registrar to Dr DK Peters (Renal Immunology), Royal Postgraduate Medical School, Hammersmith Hospital, London.
Sept 1973 - Sept 1974	Trainee in General Practice to Dr DC Barker, Chalkhill Health Centre, Wembley.
Sept 1974 - June 1976	Registrar to Dr J Fielding (Haematology), St Mary's Hospital, Harrow Road, London.
Nov 1976 - Dec 1982	Senior Registrar to Professor PT Flute, Department of Haematology, St George's Hospital Medical School, London (6/10) including appointments at St James' Hospital Balham, Royal Marsden Hospital Sutton, and the South London Blood Transfusion Centre.
Jan 1983 - Oct 1984	Research Senior Registrar to Dr PBA Kernoff and Dr HC Thomas, Royal Free Hospital, and Honorary Lecturer, Royal Free Hospital School of Medicine. Action Research Fellowship.
Nov 1984 - Nov 1987	Senior Lecturer in Haematology, Charing Cross and Westminster Medical School, and Honorary Consultant Haematologist, Queen Mary's University Hospital, Roehampton, London.
Sept 1985 - Nov 1987	AIDS Counsellor, Richmond, Twickenham and Roehampton Health District.
April 1986 - Nov 1987	Honorary Consultant in Haematology, Haemophilia Centre and Haemostasis Unit, Royal Free Hospital: 2 sessions/week.
Nov 1987 - Dec 2005	Consultant Haematologist, Haemophilia Centre and Haemostasis Unit, Royal Free Hospital.
April 1991 - April 1992	Acting Director Haemophilia Centre and Haemostasis Unit, Royal Free Hampstead NHS Trust.
April 1992 – Dec 2005	Director Haemophilia Centre and Haemostasis Unit, Royal Free Hampstead NHS Trust.

Jan 2006 - present	Emeritus Professor of Haemophilia, University College London
April 2007 – April 2010	Honorary Consultant Haematologist Oxford Haemophilia and Thrombosis Centre Responsibility for clinic for women with inherited bleeding disorders.

RESEARCH GRANTS

PEER REVIEWED

July 1988	£11,000. Haemophilia Society. Antenatal Diagnosis using DNA analysis.
Sept 1988	£25,000. Medical Research Council. Study of zidovudine in asymptomatic haemophiliacs infected with HIV.
Sept 1989	£25,000. Medical Research Council. Study of Zidovudine in asymptomatic haemophiliacs infected with HIV.
March 1990	£15,000 Medical Research Council. Detection of strains of human immunodeficiency virus resistant to zidovudine.
Sept 1990	£60,000. Medical Research Council. Study of zidovudine in asymptomatic haemophiliacs infected with HIV.
Oct 1991	£10,000. Haemophilia Society For investigation of HCV disease in haemophilia.
Oct 1991	£61,000. Medical Research Council Project Grant Follow-up of a cohort of anti-HIV seropositive haemophiliacs for up to 15 years from seroconversion.
Dec 1991	£77,000. Medical Research Council Participation in MRC Clinical Trials in AIDS and HIV.
March 1992	£58,000. Department of Health Commissioned report of study entitled 'Costing the care of HIV infection.'
July 1993	£177,000. Medical Research Council Project Grant with Professor G Goldspink and Professor P Butterworth. Gene therapy using skeletal muscle as an in vivo expression system.
Jan 1994	330,000 ECU (Royal Free Hospital 125,000 ECU). Commission of the European Communities. "Coping with Physical Illness with a Particular Focus on Blood Dyscrasias". UK Applicants Professor B Taylor, Dr C Lee. Cross National Co-ordinator Professor I Kolvin. A study in collaboration with Professor Mannucci, Milan and Professor Tsiantis, Athens.
June 1997	1,190,000 ECU (Royal Free Hospital Medical School 140,000 ECU) "Optimising orphan drug therapy in severe forms of von Willebrand disease" A study in collaboration with University of Milan, LFB France, University of Lund, University of London, University of Frankfurt, University of Lille, ITBA Italy.
1998 – 2001	£131,959 Medical Research Council (collaborator) "The impact of new therapies on the natural history of disease and survival after HIV-1 infection" (10 investigators)
July 1998	Medical Research Council Strategic Grant: The Course of Viral Load Throughout HIV-1 Infection
July 1998	European Commission Contract of Associated BMH4-CT97-2550 Collaborative Group on AIDS Incubation and HIV Survival (259,998 ECU, UCL).
Dec 2000 – Nov 2005	£108,264 Medical Research Council Co-operative Grant HIV infection : New insights in the therapeutic era (nine Investigators).

Jan 2002 – 2006 £137,000
 Department of Health Research & Development Grant
 vCJD, Prevalence Studies in Haemophiliacs on behalf of UK Haemophilia Doctors
 Organisation

KATHARINE DORMANDY TRUST

Ms Helen L Devereux 1992 - 1996	'The molecular biology of HCV infection in haemophilia' £60,000
Ms Ricarda Steinbrecher 1992 - 1994	'Study of myosin heavy chain genes in mammalian muscle and the characteristics of the different isoform genes and their regulation during development.' £60,000
Ms Gaynor Miller 1993 - 1997	'To construct genes using muscle promoters and signal sequences for the purposes of gene therapy using muscle as the in vivo expression system.' £35,000
Mr Alexander Miners 1995 - 1998	'The economics of haemophilia care' £35,000
Dr Rezan Kadir 1995 – 1998	'Obstetrics and gynaecological problem in patients with disorders of haemostasis' £20,000
Ms Zoe Kinson 1996 – 1997	'Viral interactions in haemophilia: HGV, HBV, HCV & HIV' £20,000
Mr Esteban Herrero 1998-2001	'The molecular basis of HIV and HCV Interaction in Haemophilia.' £45,000

COMMERCIAL SPONSORSHIP

1988	£2,000	Merck Sharp and Dohme. Antibody response to hepatitis B vaccination in haemophiliacs.
1989	£2,000	Wellcome Trust Study of HIV-related thrombocytopenia.
1995	£15,000	Baxter Pharmacokinetics of Hemophil M
1995	£50,000	Genetics Institute Recombinant FIX PUP and PTP study
1995	£20,000	Pharmacia Upjohn Recombinant FVIII PUP study
1995	£20,000	Bayer Constant infusion FVIII in surgery
1996	£75,000	Ferring Menorrhagia, bleeding disorders and use of DDAVP
2000 – 2003	£90,000	Novo Nordisk Study of FXI deficiency

COMMITTEES

ROYAL FREE HAMPSTEAD NHS TRUST

Member, Audit Committee	1991 - 1995
Member, Management Committee, Gray's Inn Division	1995 - 2000
Member, Drug and Therapeutics and New Technologies Committee	1995 - 2005
Chairman, HIV/AIDS Specialty Group	1997 - 2000
Member, Medical Advisory Committee	1997 - 2000
Member, Clinical Service Group - Oncology & Blood Disorders	2000 - 2002
Member, Clinical Service Group – Medicine II	2002 - 2005

ROYAL FREE HOSPITAL SCHOOL OF MEDICINE

Member, Education Committee	1987 - 1998
Member, School Council	1992 - 1995
Member, Media Committee	1995 - 1997

REGIONAL - NE THAMES / LONDON

Regional Working Party, HIV infection	1988 – 1992
Member, Advisory Committee on Distinction Awards	1992 – 1995
Member, committee developing service specification for Pan Thames Haemophilia Consortium	2000 – 2001
Member, Expert Advisory Group for Pan Thames Haemophilia Consortium	2000 – 2004
Member, Pan Thames Haemophilia Consortium Service Review Steering Group	2002 – 2003

NATIONAL

National UK Working Party - Organisation of haemophilia care	1986 – 1990
National Working Party - MRC Concorde Trial	1988 – 1991
MRC HIV Infection and AIDS Clinical Trials Working Party	1991 – 2005
Joint Parliamentary Group on AIDS	1989 – 2005
United Kingdom Haemophilia Doctors Committee (UKHCDO)	1991 – 2005
Chairman, HIV Working Party, UKHCDO	1993 – 1999
Hepatitis Working Party, UKHCDO	1993 – 1999
Member, Medical Advisory Panel, Haemophilia Society of UK	1993 – 2005
Member, Scientific Committee, British HIV Association	1997 - 2000
Member, Board of Examiners, Haematology, Royal College of Pathologists	1997 – 2004
Member, Organising Committee, King's Fund conference, 'Funding Rare & Expensive Treatments: the case of haemophilia'	1998
Chairman, Transfusion Transmitted Disease Working Party, UKHCDO	1999 – 2003
Examiner (one of two) for written papers of Part 1 MRCPPath	2000 – 2003
Member, Intercollegiate Committee for Haematology representing Royal College of Physicians, London	2000 – 2003
Member, COPE (Committee of Publication Ethics)	2001 – 2005
Member, Data Management Group of UKHCDO	2000 – 2005
Non-Executive Director, National Biological Standards Board	2004 - 2009
Member, Women Bleed Too, Haemophilia Society, UK	2005 – present
Member CJD Sample Oversight Committee	2009- 2013

INTERNATIONAL

Secretary	International Haemophilia Training Centres Committee, World Federation of Haemophilia	1992-1996
Chairman	International Haemophilia Training Centres Committee, World Federation of Haemophilia	1996 - 2003
Co-Chairman	International Society Thrombosis & Haemostasis (ISTH) Subcommittee on Factor VIII & IX	2001 - 2009

Member	International Society on Thrombosis and Haemostasis (ISHT) Scientific and Standardisation Committee Subcommittee on factor VIII and factor IX.	1992 - 2010
Member	SSC Subcommittee on von Willebrand Disease	1992– 2013
Auditor	External Reviewer for the Haemostasis Service provided for the National Centre for Hereditary Coagulation Disorder (NCHCD) St James' Hospital, Dublin	2001
Member	Joint World Health Organisation (WHO) and ISHT Subcommittee Coagulation Nomenclature	1992
Member	WHO, World Federation of Haemophilia (WFH), World AIDS Fund & Haemophilia Federation of India Training Workshop - 'Haemophilia and AIDS' New Delhi, January 5-7	1994
Member	WHO and WFH Faculty, 'Modern Treatment of Haemophilia', Geneva, March 21-23 Haemophilia Care in Developing Countries, June	1994 1997
Member	Scientific Organising Committee, WFH bi-annual Congress held in Dublin	1996
	Scientific Organising Committee, WFH bi-annual Congress held in Jerusalem	1998
	Scientific Organising Committee, WFH bi-annual Congress held in Montreal	2000
	Scientific Organising Committee, WFH bi-annual Congress held in Seville	2002
	Scientific Organising Committee, WFH bi-annual Congress, Bangkok	2004
Member	International Advisory Committee for the XVIIth Congress of the International Society for Thrombosis and Haemostasis, Washington	1999
	International Advisory Committee for the XVIIth Congress of the International Society for Thrombosis and Haemostasis , Paris	1999 - 2001
	International Advisory Committee for the XVIIIth Congress of the International Society for Thrombosis and Haemostasis , Birmingham	2001 - 2003
Member	Concerted Action on Sero-Conversion to AIDS and Death in Europe Steering Committee (CASCADE).	1997 - 2004
Member	World Federation of Haemophilia Executive (Special responsibility for WFH/WHO relationship)	1996 -2000
Organiser/ Rapporteur	WHO/WFH/ISTH Workshop – London, Feb 11-13	2002
Member Board	Novo Nordisk Haemophilia Foundation	2005 – 2012
Expert	Workshop on plasma derived medicinal products and vCJD risk – Oct 6-7, 2005	
Expert	GTAC advisory meeting, AAV8 delivered gene therapy for haemophilia B- Mar 24, 2006	
Expert	FVIII Inhibitor Workshop, European Medicines Evaluation Authority – Feb 27-28, 2006	
Chairperson	DSMB Phase III trial BAY 79 4980 (Bayer Health Care)	2006 – 2009
Member	DSMB The VWD International Prophylaxis (VIP) study	2006- 2012
Chairperson	DSMB NN (Novo Nordisk)1731-1804, recombinant VIIa analogue study	2007- 2010
Chairperson	DSMB NNF13CD-1725, recombinant F13 study	2008-2009
Chairperson	DSMB NN7128-1907, long acting recombinant VIIa study	2009- 2010
Member	DSMB 998HA301 A-LONG Biogen Idec	2010- 2012

INTERNATIONAL HAEMOPHILIA TRAINING CENTRES (IHTC)

The Katharine Dormandy Haemophilia Centre and Haemostasis Unit is one of 25 such centres worldwide and training is provided to fellows annually, awarded by competition.

Secretary	IHTC organising committee	1992-1996
Chairman		1996-2003

WORKSHOPS

1994 October	Participant, WFH workshop on the management of haemophilia held in Jakarta, Indonesia attended by 150 doctors from all over Indonesia.
1995 January	Organiser of workshops in Delhi and Poona, India, for the Haemophilia Society of India. Approximately 100 doctors from India and Nepal participated in each 3-day workshop.
1996 March	Participant in a WFH workshop held in Johannesburg, South Africa, attended by health care providers, including doctors, from all over Africa.
1998 October	Organiser and participant, WFH workshop held in Karachi and Lahore, Pakistan, attended by 400 health care professionals including doctors from all over Pakistan.
1999 November	Organiser and participant, WFH workshop held in Tehran and Isfahan, Iran.
2000 November	Organiser and participant, workshop held in Hong Kong, supported by the WFH, Katharine Dormandy Trust and University of Hong Kong.
2003 April	Participant, Aventis Behring workshop London - ' <i>Is prophylaxis in von Willebrand disease warranted?</i> '
2005 October	Participant and speaker at expert workshop on plasma-derived and other medicinal products and vCJD risk, European Medicines Agency (EMA)
2006 March	Participant at expert workshop on factor VIII products and inhibitor development, European Medicines Control Agency (EMA)

SOCIETIES

British Society of Haematology
 British Society for Thrombosis and Haemostasis
 British Association for the Study of the Liver
 World Federation of Haemophilia
 International Society on Thrombosis and Haemostasis
 British HIV Association

JOURNALS

Founding editor *HAEMOPHILIA*, the official bimonthly official journal of the World Federation of Haemophilia and European Association for Haemophilia and Allied Disorders - launched by Blackwell Science, October 1994 and now published by Wiley-Blackwell. Listed in Current Contents/Clinical Medicine and on Medline.

Member, Editorial Board *AIDS Care*.
 Editorial Board *HIV Medicine*

Reviewer for the following journals:

British Journal of Haematology
Thrombosis and Haemostasis
Journal of Clinical and Laboratory Haematology
Gut

AIDS
European Journal of Gastroenterology and Hepatology
Journal of Medical Virology
Nature
The Postgraduate Medical Journal
Acta Haematologica
Journal of Psychosomatic Research
Alimentary Pharmacology and Therapeutics
Gastroenterology
Blood
American Journal of Hematology
Journal Thrombosis and Haemostasis

PUBLICATIONS

THESIS

MD Thesis, University of London 1989

'The Diagnosis, Natural History, Prevention and Treatment of Viral Hepatitis in Haemophilic Patients'

SCIENTIFIC PAPERS

1976 Disseminated intravascular coagulation associated with polycythemia rubra vera.

Lee CA, Moss S.

Proceedings of the Royal Society of Medicine 1976; 69: 521.

1984 Acquired hypogammaglobulinaemia and sarcoidosis.

Lee CA.

Postgraduate Medical Journal 1984; 61: 49-51.

1985 Acute fulminant non-A non-B hepatitis leading to chronic active hepatitis after treatment with cyroprecipitate.

Lee CA, Kernoff PBA, Karayiannis P, Thomas HC.

Gut 1985; 26: 639-641.

High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin.

Kernoff PBA, **Lee CA**, Karayiannis P, Thomas HC.

British Journal of Haematology 1985; 60: 469-479.

Relationship between blood product exposure and immunological abnormalities in English haemophiliacs.

Lee CA, Kernoff PBA, Janossy G, Bofill CR, Thomas HC, Rizza CR.

British Journal of Haematology 1985; 60: 161-172.

The interactions between hepatotropic viruses in patients with haemophilia.

Lee CA, Kernoff PBA, Karayiannis P, Farci P, Thomas HC.

Journal of Hepatology 1985; 1: 379-384.

Cryoglobulinaemia in haemophilia.

Lee CA, Kernoff PBA, Peters DK.

British Journal of Haematology 1985; 290: 1947-1948.

1988 Non-invasive investigation of liver disease in haemophilic patients.

Miller EJ, **Lee CA**, Karayiannis P, Hamilton-Dutoit SJ, Dick R, Thomas HC, Kernoff PBA.

Journal of Clinical Pathology 1988; 41: 1039-1045.

1989 The immune response of patients with congenital coagulation disorder to hepatitis B vaccine: suboptimal response and human immunodeficiency virus infection.

Miller EJ, **Lee CA**, Karayiannis P, Holmes S, Thomas HC, Kernoff PBA.

Journal of Medical Virology 1989; 28: 96-100.

Interferon therapy for chronic non-A non-B and chronic delta liver disease in haemophilia.

Lee CA, Kernoff PBA, Karayiannis P, Thomas HC.

British Journal of Haematology 1989; 72: 235-238.

Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection.

Webster A, **Lee CA**, Cook DG, Grundy JE, Emery VC, Kernoff PBA, Griffiths PD.

Lancet 1989; ii: 63-66.

The natural history of human immunodeficiency virus infection in a haemophilic cohort.

Lee CA, Phillips A, Elford J, Miller EJ, Bofill M, Griffiths PD, Kernoff PBA.

British Journal of Haematology 1989; 73: 228-234.

A simple nebuliser modification to enhance alveolar targeting.
Simonds AK, Newman SP, Johnson MA, Talace N, **Lee CA**, Clarke SW.
Lancet 1989; ii: 953.

Treatment dilemmas for HIV infected haemophiliacs.
Lee CA, Miller R, Goldman E.
AIDS Care 1989; 1: 153-158.

Prediction of progression to AIDS by analysis of T4 lymphocyte counts in a haemophilic cohort.
Phillips A, **Lee CA**, Elford J, Janossy G, Timms A, Bofill M, Kernoff PBA.
AIDS 1989; 3: 737-741.

- 1990** Functional protein S assay shows improved correlation with clinical symptoms in hereditary deficiency.
Woodhams BJ, Matthews KB, **Lee CA**, Kernoff PBA.
Thrombosis Research 1990; 57: 651-657.

The treatment of HIV-associated thrombocytopenia in haemophiliacs.
Lim SG, **Lee CA**, Kernoff PBA.
Clinical & Laboratory Haematology 1990; 12: 237-245.

Alveolar targeting of aerosol pentamidine.
Simmonds AK, Newman SP, Johnson MA, Talace N, **Lee CA**, Clarke SW.
American Review of Respiratory Diseases 1990; 141: 827-829.

Zidovudine treatment for anti-HIV positive haemophiliacs.
Lim SG, **Lee CA**, Kernoff PBA.
Clinical & Laboratory Haematology 1990; 12: 367-378.

- 1991** Protective antibodies to hepatitis B virus in haemophiliacs.
Oon LLE, King A, Higgins JA, **Lee CA**, Kernoff PBA, Goodall AH.
Journal of Medical Virology 1991; 33: 19-25.

Serial CD4 lymphocyte counts in the development of AIDS.
Phillips AN, **Lee CA**, Elford J, Janossy G, Timms A, Bofill M, Kernoff PBA.
Lancet 1991; 337: 389-392.

Fluconazole for oro-pharyngeal candidiasis in anti-HIV positive haemophiliacs.
Lim SG, **Lee CA**, Hales M, O'Doherty M, Winter M, Kernoff PBA.
Alimentary Pharmacology & Therapeutics 1991; 5: 199-205.

More rapid progression to AIDS in older HIV infected people: the role of CD4 T-cell counts.
Phillips AN, **Lee CA**, Elford J, Webster A, Janossy G, Timms A, Bofill M, Kernoff PBA.
Journal of AIDS 1991; 4: 970-975.

Hepatitis C antibody assay (Ortho) in a longitudinal study of haemophiliacs.
Lim SG, **Lee CA**, Charman H, Tilsed G, Griffiths P, Kernoff PBA.
British Journal of Haematology 1991; 78: 398-402.

Progression of HIV disease in a haemophilic cohort followed for eleven years and the effect of treatment.
Lee CA, Phillips AN, Elford J, Janossy G, Griffiths P, Kernoff PBA.
British Medical Journal 1991; 303: 1093-6.

p24 antigenaemia, CD4 lymphocytes counts and the development of AIDS.
Phillips AN, **Lee CA**, Elford J, Webster A, Janossy G, Griffiths PD, Kernoff PBA.
AIDS 1991; 5: 1217-1222.

- 1992** The cumulative risk of AIDS as the CD4 lymphocyte count declines.
Phillips AN, **Lee CA**, Elford J, Janossy G, Griffiths P, Kernoff PBA.
Journal of Acquired Immune Deficiency Syndromes 1992; 5: 148-152

Counselling HIV positive haemophilic men who wish to have children.

Goldman E, Miller R, **Lee CA**.

British Medical Journal 1992; 304: 829-830.

Antibodies to platelet glycoproteins in haemophiliacs infected with HIV

Quadri MI, **Lee CA**, Goodall AH, Lim SG, Kernoff PBA.

Clinical & Laboratory Haematology 1992; 14: 109-120.

CMV infection, CD4+ lymphocyte counts and the development of AIDS in HIV-1 infected haemophiliacs.

Webster A, Phillips AN, **Lee CA**, Janossy G, Kernoff PBA and Griffiths PBA.

Clinical and Experimental Immunology 1992; 88: 6-9.

Laboratory Control Values for CD4 and CD8 T lymphocytes - implications for HIV-1 diagnosis.

Bofill M, Janossy G, **Lee CA**, MacDonald-Burns D, Phillips AN, Sabin C, Timms A, Johnson MA and Kernoff PBA.

Clinical and Experimental Immunology 1992; 87:1-10.

Immunodeficiency and the risk of death in HIV infection.

Phillips AN, Elford J, Sabin C, Bofill M, Janossy G and **Lee CA**.

Journal of the American Medical Association 1992 268: 2662-2666

Development and evaluation of ELISAs for factor XIIIa and XIIIb subunits in plasma.

Murdock PJ, Owens DL, Chitolie A, Hutton RA and **Lee CA**.

Thrombosis Research 67; 73-79, 1992.

1993 The children of HIV positive haemophilic men.

Goldman E, **Lee CA**, Miller R, Kernoff P, Morris-Smith J and Taylor B.

Archives of Disease in Childhood 1993 68: 133-4

A family with HIV and haemophilia

Goldman E, Miller R, **Lee CA**.

AIDS Care 1993, 5: 81-87

The progression of HIV disease in a haemophilic cohort

Sabin C, Phillips A, Elford J, Griffiths P, Janossy G, **Lee CA**.

British Journal of Haematology 83: 330-333, 1993

CD8 lymphocyte counts and serum immunoglobulin A levels early in HIV infection as predictors of CD4 lymphocyte depletion during 8 years of follow up.

Phillips AN, Sabin CA, Elford J, Bofill M, **Lee CA** and Janossy G.

AIDS 1993; 7: 975-980

A clinico-pathological audit of opportunistic viral infections in HIV-infected patients.

Pillay D, Lipman MCI, **Lee CA**, Johnson MA, Griffiths PD & McLaughlin J.

AIDS 1993; 7: 969-974

Loss of Mucosal CD4 lymphocytes is an early feature of HIV infection.

Lim SG, Condez A, **Lee CA**, Johnson, Elia C and Poulter LW.

Clinical and Experimental Immunology 1993; 92: 448-454

Adenotonsillectomy in patients with inherited bleeding disorders.

Prinsely P, Wood M and **Lee CA**.

Clinical Otolaryngology and Allied Sciences 1993; 18: 206-208

Acquired anti factor VIII inhibitors following pregnancy: a report of two cases responding to treatment.

Laffan M, Glen J, Chitolie A, Owens D, **Lee CA**.

Journal Clinical and Laboratory Haematology 1993; 15: 195-202

Intestinal permeability and function in patients infected with human immunodeficiency virus (HIV): a comparison with coeliac disease.

Lim SG, Menzies IS, **Lee CA**, Johnson MA and Pounder RE.

Scandinavian Journal of Gastroenterology 1993; 28: 573-80.

The incidence of HIV-related disease in a cohort of haemophiliacs: natural history and changes since the introduction of pre-aids treatment.

Sabin CA, Phillips AN, Elford J, Janossy G, Bofill M and **Lee CA**.
Journal Clinical and Laboratory Haematology 1993; 15: 241-251.

Lymphocyte activation in HIV-1 infection.

Janossy G, Borthwick N, Lomnitzer R, Medina E, Squire SB, Phillips AN, Lipman M, Johnson MA, **Lee CA** and Bofill M.

AIDS 1993; 7: 613 - 62

An audit of endoscopic surveillance biopsies in HIV-positive patients with gastrointestinal symptoms.

Lim SG, Lipman MCI, Squire SB, Pillay D, Gillespie S, Sankey EA, Dhillon AP, Johnson MA, **Lee CA** and Pounder RE.

Gut 1993; 34: 1429 - 1432

Acquired immunodeficiency syndrome (AIDS) risk in recent and long-standing Human Immunodeficiency Virus Type 1 (HIV-1)-infected patients with similar CD4 lymphocyte counts.

Phillips AN, Sabin CA, Elford J, Bofill M, Janossy G and **Lee CA**.
American Journal of Epidemiology 1993; 138: 870-878..

CD8+ T cell counts up to 10 years from seroconversion.

Phillips AN, Sabin CA, Bofill M, Janossy G and **Lee CA**.

Journal of AIDS 1993; 6: 1176-1177

MAP Workshop. (Participants in alphabetical order: Bird G, Cook R, De Angelis D, Farewell V, Fielding K, Fore A, Gore S, Kramer A, **Lee CA**, McNeill A, Pezzotti P, Phillips AN, Raboud J, Rezza G, Sabin C, Satten G). Extending public health surveillance of HIV infection: information from a five cohort workshop. *Statistics in Medicine* 1993; 12: 2065-2085.

MAP Workshop. (Participants in alphabetical order: Bird G, Cook R, De Angelis D, Farewell V, Fielding K, Fore A, Gore S, Kramer A, **Lee CA**, McNeill A, Pezzotti P, Phillips AN, Raboud J, Rezza G, Sabin C, Satten G). Markers as time-dependent covariates in relative risk regression. *Statistics in Medicine* 1993; 12: 2087-2098.

MAP Workshop. (Participants in alphabetical order: Bird G, Cook R, De Angelis D, Farewell V, Fielding K, Fore A, Gore S, Kramer A, **Lee CA**, McNeill A, Pezzotti P, Phillips AN, Raboud J, Rezza G, Sabin C, Satten G). Marker paths. *Statistics in Medicine* 1993; 12: 2099-2126.

MAP Workshop. (Participants in alphabetical order: Bird G, Cook R, De Angelis D, Farewell V, Fielding K, Fore A, Gore S, Kramer A, **Lee CA**, McNeill A, Pezzotti P, Phillips AN, Raboud J, Rezza G, Sabin C, Satten G). Markov models. *Statistics in Medicine* 1993; 12: 2127-2130.

1994 Beta-2 microglobulin as a predictor of prognosis in HIV infection: A proposed strategy for use in clinical practice.

Sabin CA, Phillips AN, **Lee CA**, Elford J, Bofill M and Janossy G.
British Journal of Haematology 1994; 86: 366-371.

The use of back-calculation to estimate the prevalence of severe HIV-induced immunodeficiency in England and Wales.

Sabin CA, Phillips AN and **Lee CA**.

Journal of the Royal Statistical Society, Series A 1994; 157: 41-56.

A long-term follow-up of hepatitis B vaccination in patients with congenital clotting disorders.

Pillay D, Pereira C, Sabin C, Powell L, Zuckerman AJ and **Lee CA**.
Vaccine 1994; 12: 978-983.

CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients.

Sabin CA, Pasi J, Phillips A, Elford J, Janossy G, and **Lee CA**.
Haemostasis and Thrombosis 1994; 72(2): 214-217

The progression of HCV-associated liver disease in a cohort of haemophilic patients.

Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G and **Lee CA**.

British Journal of Haematology 1994; 87: 555-561

Porcine factor VIII therapy in patients with congenital haemophilia and inhibitors: efficacy, patient selection and side effects.

Hay CRM, Lozier JN, **Lee CA**, Tradati F, Santagostino E, Ciavarella N, Fukui H, Yoshioka, Teitel J, Mannucci PM and Kasper CK.

Seminars in Haematology 1994; 31: 20-25

Analysis of intron 22 inversions of the factor VIII gene in severe haemophilia A. Implications for genetic counselling.

Jenkins PV, Collins PW, Goldman E, McCraw A, Riddell A, **Lee CA**, Pasi KJ.

Blood 1994; 84: 2197-2201.

HCV RNA levels and HIV infection: Evidence for a viral interaction in haemophilic patients.

Telfer PT, Brown D, Devereux H, **Lee CA** and DuSheiko GM.

British Journal of Haematology 1994; 88: 397-399.

Immunological markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part 1.

AIDS 1994; 8:991-921

Use of CD4 lymphocyte count to predict long term survival free of AIDS after HIV infection.

Phillips AN, Sabin CA, Elford J, Bofill M, Janossy G and **Lee CA**.

British Medical Journal 1994; 309: 309-313.

A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.

Thomas DP, Hampton KK, Dasani H, **Lee CA**, Giangrande PLF, Harman C, Mee MI and Preston FE.

British Journal of Haematology 1994; 87: 782-788.

Immunological markers of AIDS progression: consistency across five HIV-related cohorts.

MAP Workshop. (Participants in alphabetical order: Bird G, Cook R, De Angelis D, Farewell V, Fielding K, Fore A, Gore S, Kramer A, **Lee CA**, McNeill A, Pezzotti P, Phillips AN, Raboud J, Rezza G, Sabin C, Satten G).

AIDS 1994; 8:911-921.

Immunological marker paths for seroconversion: single determinations of immunological A and beta-2-microglobulin are not adequate to estimate time of HIV infection

MAP Workshop. (Participants in alphabetical order: Bird G, Cook R, De Angelis D, Farewell V, Fielding K, Fore A, Gore S, Kramer A, **Lee CA**, McNeill A, Pezzotti P, Phillips AN, Raboud J, Rezza G, Sabin C, Satten G).

AIDS 1994; 8: 923-933.

1995 The effect of CMV infection on progression of human immunodeficiency virus disease in a cohort of haemophilic men followed for up to 13 years from seroconversion.

Sabin CA, Phillips AN, **Lee CA**, Janossy G, Emery V, Griffiths PD.

Epidemiology & Infection 1995; 114: 361-372

Bleeding complications following tonsillectomy in severe von Willebrand's disease.

Alusi GH, Grant WE, **Lee CA**, Pasi KJ and Stearns MP.

Journal of Laryngology & Otology 1995; 109: 437-439

Clinical experience with a high purified factor IX concentrate in patients undergoing surgical operations.

Thomas DP, **Lee CA**, Colvin BT, Dasani H, Dolan G, Giangrande PLF, Jones P, Lucas G, Cantwell O and Harman CT.

Haemophilia 1995; 1: 17-23

Presence of CD3+CD8+BC1-2 (low) lymphocytes undergoing apoptosis and activated macrophages in lymph nodes of HIV-1 +ve patients.

Bofill M, Gombert W, Borthwick NJ, Akbar AN, McLoughlin LE, **Lee CA**, Johnson MJ, Pinching AJ, Janossy G

American Journal of Pathology 1995; 146: 1542-1555

Prophylaxis for *Pneumocystis carinii* pneumonia: its impact on the natural history of HIV infection in men with haemophilia.

Sabin CA, Elford J, Phillips AN, Janossy G and **Lee CA**.

Haemophilia 1995; 1: 37-44

Hepatitis C genotypes in haemophilic patients treated with alpha-interferon.

Devereux H, Telfer P, Dusheiko G, **Lee CA**.

Journal of Medical Virology 1995; 45: 284-287.

Alpha interferon for hepatitis C infection in haemophilic patients.

Telfer P, Devereux H, Colvin B, Hayden S, Dusheiko G and **Lee CA**.

Haemophilia 1995; 1: 54-58

Staging system for clinical AIDS patients.

Mocroft AJ, Johnson MA, Sabin CA, Lipman M, Elford J, Emery V, Morcinek J, Youle M, Janossy G, **Lee CA** and Phillips AN.

Lancet 1995; 346: 12-17

Hospital costs of treating haemophilic patients infected with HIV.

Kennelly JM, Tolley KH, Ghani ACH, Sabin CA, Maynard AK and **Lee CA**.

AIDS 1995; 9: 787-793

Chronic hepatitis C infection in haemophilic patients: Clinical significance of viral genotype

Telfer PT, Devereux H, Savage K, Scott F, Dhillon AP, Dusheiko G and **Lee CA**.

Thrombosis and Haemostasis 1995; 94: 1259-64

Expression of factor VII by muscle cells in vitro and in vivo following direct gene transfer: modelling gene therapy for haemophilia

Miller G, Steinbrecher RA, Murdock PJ, Tuddenham GD, **Lee CA**, Pasi KJ and Goldspink G.

Gene Therapy 1995; 2: 736-742

1996 Comparison of immunodeficiency and AIDS-defining conditions in HIV negative and HIV positive men with haemophilia A.

Sabin CA, Pasi KJ, Phillips AN, Lilley P, Bofill M, **Lee CA**.

British Medical Journal 1996; 312: 207-212.

The use of intermediate purity clotting factor concentrates and HIV disease progression in men with haemophilia.

Sabin CA, Pasi J, Phillips AN, Lilley P, Elford and **Lee CA**.

Haemophilia 1996; 2: 78-81

Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia A and inhibitors: The results of an international survey.

Hay CRM, Lozier JN, **Lee CA**, Laffan M, Tradati F, Santagostino E, Ciavarella N, Schiavoni M, Fukui H, Yoshioka A, Teitel J, Mannucci PM and Kasper CK.

Thrombosis & Haemostasis 1996; 75: 25-2.

Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to a recombinant capsid protein and a latent immunofluorescence antigen.

Guy R Simpson, Thomas F Schulz, Denise Whitby, Pamela M Cook, Chris Boshoff, Lucille Rainbow, Mark R Howard, Shou-Jiang Gao, Roy A Bohenzky, Peter Simmonds, **Christine Lee**, Annemiek de Ruiter, Angelos Hatzakis, Richard S Tedder, Ian V D Weller, Robin A Weiss and Patrick S Moore.

Lancet 1996; 349: 1133-38

The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. Alpha International Coordinating Committee.

AIDS 1996; 10: 867-880

Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals.

Delta Coordinating Committee.

Lancet 1996; 348: 283-291

Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate.

Yee TT, Cohen BJ, Pasi KJ and **Lee CA**

British Journal of Haematology 1996; 93: 457-459

Longitudinal genotype analysis and quantification of hepatitis C virus in haemophilic patients receiving alpha-interferon therapy.

Devereux H, Telfer P, Brown D, Morris A, Dusheiko G, Emery V and **Lee CA**.

Journal of Viral Hepatitis 1996; 3: 43-48

Increased numbers of primed activated CD8+CD38+CD45 RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients.

Bofill M, Mocroft A, Lipman m, Medina E, Borthwick NJ, Sabin CA, Timms A, Winter M, Baptista L, Johnson MA, **Lee CA**, Phillips AN and Janossy G.

AIDS 1996; 10: 827-834

Hope for haemophilic patients with hepatitis

Lee CA

GUT 1996; 39: 887-888

Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M.

Lee CA, Barrowcliffe T, Bray G, Gomperts E, Hubbard A, Kemball-Cook G, Lilley P, Owens D, Von Tilberg L and Pasi J.

Thrombosis and Haemostasis 1996; 76: 950-956

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study.

Dusheiko G, Main J, Thomas H, Reichard O, **Lee C**, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sillikens P and Weiland O.

Journal of Hepatology 1996; 25: 591-598

- 1997** The association between hepatitis C virus genotype and human immunodeficiency virus (disease progression in a cohort of haemophilic men.

Sabin CA, Telfer P, Phillips AN, Bhagani S and **Lee CA**.

Journal of Infectious Disease 1997; 175: 164-8

Long-term evolution of the 5' UTR and a region of NS4 containing a CTL epitope of hepatitis C virus in two haemophilic patients

Devereux HL, Brown D, Dusheiko GM, Emery VC and **Lee CA**.

Journal of General Virology 1997; 78: 583-590

CD8+, CD38+ Lymphocyte percent: A useful immunological marker for monitoring HIV-1 infected patients

Mocroft A, Bofill M, Lipman M, Medina E, Borthwick N, Timms A, Batista L, Winter M, Sabin C, Johnson M, **Lee CA**, Phillips AN and Janossy G.

JAIDS 1997; 14: 158-162

Acquired haemophilia, an unusual cause of severe postpartum haemorrhage

Kadir RA, Koh MB, **Lee CA** and Pasi KJ.

British J Obs & Gynae 1997; 104: 854-856

Survival after a very low (< 5 cells/mm³) CD4+ T-cell count in individuals infected with HIV

Sabin CA, Mocroft A, Bofill Margarita, Janossy G, Johnson M, **Lee CA** and Phillips AN.

AIDS 1997; 11: 1123-1127

Protease inhibitors and unusual bleeding in haemophiliacs.

Yee TT, Amrolia PJ, **Lee CA**, Mir N and Giangrande PL.

Haemophilia 1977; 3: 219-221

Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product.

Yee TT, Williams MD, Hill FG, **Lee CA** and Pasi KJ.

Thrombosis and Haemostasis 1997; 88: 1027-1029

Identification and eradication of *Helicobacter pylori* infection in haemophilic patients.

Lee CK, Wyeth J, Sercombe J, Pasi KJ, **Lee CA** and Pounder RE.

Haemophilia 1997; 3: 288-291

Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency.

Evans G, Pasi KJ, Mehta A, **Lee CA** and Perry DJ.

Blood Coagulation and Fibrinolysis 1997; 8: 437-440.

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C.

Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR, Dusheiko GM, **Lee CA**, Ludlam CA and Preston FE.

Lancet 1997; 350: 1425-1431

The obstetric experience of carriers of haemophilia.

Kadir RA, Economides DL, Braithwaite J, Goldman E and **Lee CA**.

British Journal of Obstetrics & Gynaecology 1997; 104: 803-810

Financing the rising cost of haemophilia care at a large comprehensive care centre.

Miners AH, Sabin CA, Stevens AJ, Tolley KH and **Lee CA**.

Journal of the Royal College of Physicians of London 1997; 31:6: 640-644

Relationship between soluble CD30 levels measured soon after HIV seroconversion and disease progression in men with haemophilia.

Sabin CA, Bofill M, Phillips AN, Elford J, Janossy G and **Lee CA**.

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997; 16: 279-283

Orthopaedic surgery in hemophilic patients with human immunodeficiency virus.

Phillips AM, Sabin CA, Ribbans WJ and **Lee CA**.

Clinical Orthopaedics and Related Research 1997; 343: 81-87

1998 The changing patterns of factor VIII (FVIII) and factor IX (FIX) clotting factor usage in a comprehensive care centre between 1980 and 1994.

Miners AH, Sabin CA, Tolley KH and **Lee CA**.

Haemophilia 1998; 4: 4-9

Frequency of inherited bleeding disorders in women with menorrhagia

Kadir RA, Economides DL, Sabin CA, Owens D and **Lee CA**.

Lancet 1998; 351: 485-89

Outcome of orthotopic liver transplantation in patients with haemophilia

Gordon FH, Mistry PK, Sabin CA and **Lee CA**.

Gut 1998; 42: 744-749

Myosin regulatory elements as vectors for gene transfer by intramuscular injection

Skarli M, Kiri A, Vrbova G, **Lee CA** & Goldspink G

Gene Therapy 1998; 5:514-520

Pregnancy in women with von Willebrand's disease or factor XI deficiency

Kadir RA, **Lee CA**, Sabin CA, Pollard D & Economides DL

British Journal of Obstetrics and Gynaecology 1998; 105: 314-321

The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: A prospective cohort comparison

Hay CRM, Ludlam CA, Lowe GDO, Mayne EE, Lee RJ, Prescott RJ and **Lee CA**.

British Journal of Haematology 1998; 101: 632-637

1998 revision to the British HIV Association for antiretroviral treatment of HIV seropositive individuals

Brian Gazzard, Graeme Moyle on behalf of the BHIVA Guidelines Writing Committee

The Lancet Vol 352; July 25, 1998

Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men.

Sabin CA, Devereux H, Phillips AN, Janossy G, Loveday C and **Lee CA**.
AIDS 1998; 12: 1347-1352

The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count

Lepri AC, Sabin CA, Phillips AN, **Lee CA**, Pezzotti P, Rezza G and the Italian Seroconversion Study.
Epidemiol & Infect (1998), 121: 369-376

Quality of life during menstruation in patients with inherited bleeding disorders.

Kadir RA, Sabin CA, Pollard D, **Lee CA** and Economides DL.
Haemophilia 1998; 4: 836-841

Changes in lymphocyte subsets in human immunodeficiency virus – positive persons with <5 CD4 T lymphocytes/mm³.

Sabin CA, Mocroft A, Bofill M, Janossy G, **Lee CA**, Johnson M and Phillips AN.
The Journal of Infectious Diseases **1998; 178: 1166-9**

Clinical experience with use of clotting factor concentrate in oral anticoagulant reversal - an audit.

Nitu I, **Lee CA**, Pasi KJ and Perry DJ.
Clinical & Laboratory Haematology 1998; 6: 363-8

Retrospective Neuropathological Review of Prion Disease in UK Haemophilic Patients

Christine A Lee, James W Ironside, Jeanne E Bell, Paul Giangrande, Christopher Ludlam, Margaret M Esiri, and James McLaughlin,
Thromb & Haemostasis 1998; 80: 909-11

Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's Disease (vWD)

Miners AH, Sabin CA, Tolley KH and **Lee CA**.
Journal of Internal Medicine 1998; 244: 515-522

The influence of HIV-1 infection on GBV-C infection in multiply infected haemophilic patients.

Devereux H, Sabin CA, Kinson Z, Brown D, Griffioen A, Dusheiko GM and **Lee CA**.
Journal of Medical Virology 1998; 56: 316-320

Factor VIII inhibitors in haemophilic patients at the Katharine Dormandy Haemophilia Centre over a 34 year period, (1964-1977).

Yee TT, Pasi KJ, Lilley PA and **Lee CA**.
Brit J Haemat 1999; 104: 909 - 914

1999 Assessing health-related quality-of-life in patients with severe haemophilia A and B

Miners AH, Sabin CA, Tolley KH, Jenkinson C, Ebrahim S and **Lee CA**.
Psychology, Health and Medicine (1999); 4: 5-15

Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders.

RA Kadir, DL Economides, CA Sabin, D Pollard, **CA Lee**.
Haemophilia 1999; 5: 40-48

Management of liver failure in a haemophilic patient co-infected with human immunodeficiency and hepatitis C viruses

Nitu IC, **Lee CA**, Dhillon AP and Mistry PK
Clin Lab Haem 1999; 21: 139-141

Shorter survival in HIV-positive patients with diarrhoea who excrete adenovirus from the GI tract.

Sabin CA, Clewley GS, Deayton JR, Mocroft A, Johnson MA, **Lee CA**, McLaughlin JE and Griffiths PD.
Journal of Medical Virology 1999; 58: 280-285

Novel cationic lipidic peptide dendrimer vectors *In vitro* delivery

Toth I, Sakthivel T, Wilderspin AF, Bayele H, O'Donnell M, Perry DJ, Pasi KJ, **Lee CA**, and Florence AT.
STP Pharma Sciences 1999; 9 (1): 93-99

Recombinant clotting factors in the treatment of haemophilia

Lee CA

Thrombosis and Haemostasis 1999; 82 (2): 516-524

Pharmacokinetics of recombinant factor VIII (Recombinate) using one-stage clotting and chromogenic factor VIII assay

Lee CA, Owens D, Bray G, Giangrande P, Collins P, Hay C, Gomperts E, Schroth P and Barrowcliffe T
Thrombosis and Haemostasis 1999; 82: 1644-7

Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders

Wilde JT, **Lee CA**, Collins P, Giangrande PLF, Winter M and Shiach CR.

Brit J Haemat 1999; 107: 556-559

Variations in coagulation factors in women: effects of age, menstrual cycle and combined oral contraceptive

Kadir RA, Economides DL, Sabin CA, Owens D and **Lee CA**

Thrombosis and Haemostasis 1999; 82: 1456-61

Creation of a novel donor splice site in intron 1 of the factor VIII gene leads to activation of a 191 bp cryptic exon in two haemophilia patients

Bagnall RD, Waseem NH, Green PM, Colvin B, **Lee CA** and Giannelli F.

Brit J Haem 1999; 107: 766-771.

Acquired von Willebrand syndrome – report of 10 cases and review of the literature

Nitu-Whalley IC and **Lee CA**

Haemophilia 1999; 5: 318-327

Audit of clinical management of von Willebrand disease during 1997 at a single institution and review of treatment patterns between 1980 and 1997

Nitu-Whalley IC, Miners AH and **Lee CA**

Haemophilia 1999; 5: 327-334

Assessing health-related quality-of-life in individuals with haemophilia

Miners AH, Sabin CA, Tolley KH, Jenkinson C, Kind P and **Lee CA**

Haemophilia 1999; 5: 378-386

2000 Reproductive choices of women in families with haemophilia

Kadir RA, Sabin CA, Goldman E, Pollard D, Economides DL and **Lee CA**

Haemophilia 2000; 6: 33-41

Type 1 von Willebrand Disease – a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history.

Nitu-Whalley I, **Lee CA**, Griffioen A, Jenkins PV and Pasi KJ

Brit J Haemat 2000; 108:259-264

Course of viral load throughout HIV-1 infection

Sabin CA, Devereux H, Phillips AN, Hill A, Janossy G, **Lee CA** & Loveday C.

JAIDS 2000; 23: 172-177

Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent?

Miners AH, Sabin CA, Tolley KH, **Lee CA**.

J Int Med 2000; 247: 493-499

Coping styles in families with haemophilia

Miller R, Sabin CA, Goldman E, Clemente C, Sadowski H, Taylor B and **Lee CA**.

Psychology Health and Medicine 2000; 5: 3-12

Cytomegalovirus Seropositivity and Human Immunodeficiency Virus Type 1 RNA Levels in Individuals with Hemophilia

Sabin CA, Devereux H, Clewley G, Emery VC, Phillips AN, Loveday C, **Lee CA** and Griffiths PD

JID 2000; 181: 1800-3

Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy

Sabin CA, Yee TT, Devereux H, Griffioen A, Loveday C, Phillips AN and **Lee CA**
AIDS 2000; 14: 1001-1007

Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men.

Prins M, Sabin CA, **Lee CA**, Devereux D and Coutinho RA.
AIDS 2000; 14: 1829-1837

A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period.

Yee TT, Taher A, Pasi KJ and **Lee CA**.
Clin Lab Haem 2000; 22: 275-278

Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time in observational studies: results from CASCADE

AIDS 2000; 14: 1899-1906

The effects of the 32 bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia

Pasi KJ, Sabin CA, Jenkins PV, Devereux HL, Ononye c and **Lee CA**
Brit J Haemat 2000; 111: 136-142

The natural history of HCV in a cohort of haemophilic patients infected between 1961-1985

Yee TT, Sabin CA, Griffioen A, Dusheiko G and **Lee CA**
Gut 2000; 47: 845-851

Identification of type 2 von Willebrand Disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling.

Nitu-Whalley IC, Riddell A, **Lee CA**, Pasi KJ, Owens D, Enayat MS, Perkins SJ and Jenkins PV.
Thrombosis & Haemostasis 2000; 84: 998-1004

Time from HIV-1 seroconversion to AIDS and death before the widespread use of highly active antiretroviral therapy: a collaborative re-analysis.

Collaborative Group on AIDS incubation and HIV survival.
Lancet 2000; 355: 1131-7

Survival after introduction to HAART in people with known duration of HIV infection.

CASCADE Collaboration
Lancet 2000; 355: 1158-9

Changes in the uptake of antiretroviral therapy and survival in persons with known duration of HIV infection in Europe.

CASCADE Collaboration
HIV Medicine 2000; 1: 224-31

Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time in observational studies: results from CASCADE.

CASCADE Collaboration
AIDS 2000; 14: 1899-1906

Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.

International Collaboration on HIV & Cancer
J Natl Cancer Inst 2000; 92: 1823-30

Markers of HIV-1 disease progression in individuals with haemophilia coinfecting with hepatitis C virus : a longitudinal study

Sabin C, Griffioen A, Yee TT, Emery VC, Herrero-Martinez E, Phillips AN , **Lee CA**
Lancet 2002 360: 1546-51

2001 Multiple myeloma and human immunodeficiency virus-1 (HIV-1) infection.

Yee TT, Murphy K, Johnson M, Abdalla SH, Patton GS, **Lee CA** and Mehta AB
Amer J Haem 2001;66:123-125

A retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease

Nitu-Whalley IC, Griffioen A, Harrington C and **Lee CA**

Amer J Haem 2001;66:280-284

Human IL-18 Receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes.

Chan W L, Pejnovic N, **Lee C A** & Al-Ali N A.

The Journal of Immunology, 2001,176: 1238-1244

Treatment of haemophilia in the UK 1981-1996

Rizza CR, Spooner RJD, Giangrande PLF on behalf of the **UKHCDO**

Haemophilia (2001) 7, 349-359

Relationships among the detection of p24 antigen, human immunodeficiency virus (HIV) RNA level, CD4 cell count and disease progression in HIV-infected individuals with haemophilia.

Sabin CA, Lepri AC, Devereux H, Phillips AN, Loveday C, **Lee CA**

The Journal of Infectious Diseases 2001; 184:511-4

Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia

Makris M, Baglin T, Dusheiko G, Giangrande PLF, **Lee CA**, Ludlam CA, Preston FE *et al*

Haemophilia (2001) 7, 339-345

Assessing the relationship between productivity levels and severity of haemophilia

Miners AH, Sabin CA, Tolley KH, Parnaby A, **Lee CA**

Haemophilia (2001) 7,459-463

Human recombinant factor IX: safety & efficacy studies in haemophilia B patients previously treated with plasma-derived factor IX concentrates.

Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL, for the **Human recombinant factor IX study group**

Blood 2001; 98:3600-3606

Treatment of haemophilia in the UK 1981-1996

Rizza CR, Spooner RJD, Giangrande PLF on behalf of the **UK Haemophilia Centre Doctors' Organisation (UKHCDO)**

Haemophilia 2001;7:349-359

Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes

Chan WL, Pejnovic N, **Lee CA**, Al-Ali NA

J Immunol 2001; 167:1238-1244

The relationships between the HIV test interval, demographic factors and HIV disease progression.

CASCADE European Collaborative Project

Epidemiology and Infection 2001; 127: 91-100

Relationships among the detection of p24 antigen, human immunodeficiency virus (HIV) RNA level, CD4 cell count and disease progression in HIV-infected individuals with haemophilia.

Sabin CA, Cozzi Lepri A, Devereux H, Phillips AN, Loveday C, **Lee CA**.

Journal of Infectious Diseases 2001; 184: 511-514

Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?

CASCADE Collaboration

JAIDS 28 : 158-165 ; 2001

2002 Experience of Prophylaxis treatment in children with severe haemophilia

Yee TT, Beeton K, Griffioen A, Harrington C, Miners A, **Lee C A**, Brown SA

Haemophilia (2002), 8, 1-7

In vivo HIV-1 compartmentalisation: drug resistance-associated mutation distribution.

Devereux HL, Burke A, **Lee CA**, Johnson MA

Journal of Medical Virology 2002; 66 : 8-12

Somatic gene therapy for haemophilia : some counselling issues for today and tomorrow.

Miller R, Fields PA, Goldspink G, **Lee CA**, Pasi JK, Perry DJ.

Psychology, Health & Medicine 2002; 7: 2, 163-173

Inverse relationship between plasma von Willebrand factor and soluble P selectin in patients with type 1 but not type 2 von Willebrand disease

Blann AD, Nitu-Whalley IC, **Lee CA** and Lip GYH.

Am J Hematology 2002, 69: 135-137

Single-dose pharmacokinetics of porcine factor VIII (Hyate C)

Hermans C, Owens D, Lilley P, Longo G, Morfini M, **Lee CA**

Haemophilia 2002; 8 (suppl 1) : 33-38

Use of the collagen binding assay for von Willebrand factor (vWF:CBA) in the analysis of type 2M von Willebrand disease: A comparison with the Ristocetin Co-Factor Assay.

Riddell AF, Jenkins PV, Nitu-Whalley IC, McCraw AH, **Lee CA** and Brown SA.

Brit J Haematol 2002; 116: 187-192

Long term patterns of hepatitis C virus RNA concentrations in a cohort of HIV seronegative men with bleeding disorders.

Sabin CA, Emery V, Devereux HL, Griffioen A, Bishop J, Dusheiko G, Yee TT, Herrero-Martinez E, **Lee CA**

J Med Virol 2002; 68:68-75

The incidence of Lymphoma in the UK haemophilia population between 1978 & 1999.

Wilde JT, **Lee CA**, Darby SC, Kan SW, Giangrande P, Phillips AN, Winter M, Spooner R, Ludlam CA, on behalf of the UKHCDO

Aids 2002, 16 : 1803-1807

Markers of HIV disease progression in individuals with haemophilia co-infected with hepatitis C virus : a longitudinal study.

Sabin CA, Griffioen A, Yee TT, Emery VC, Herrero-Martinez E, Phillips AN , **Lee CA**

Lancet 2002; 360: 1546-51.

Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.

CASCADE Collaboration

International Journal of Epidemiology 2002; 31 : 951-958

2003 The illness perceptions and treatment beliefs of individuals with severe haemophilia and their role in adherence to home treatment.

Llewellyn C, Miners A, **Lee C**, Harrington C, Weinman J

Psychology and Health 2003; 18 No.2 : 185-200

Determinants of survival following HIV-1 seroconversion after the introduction of HAART.

CASCADE collaboration.

Lancet 2003; 362: 1267-74

The role of platelet function analyser (PFA-100™) in the characterisation of patients with von Willebrand's disease and its relationships with von Willebrand factor and the ABO blood group.

Nitu-Whalley IC, **Lee CA**, Brown SA, Riddell A, Hermans C

Haemophilia 2003; 9 : 298-302

A modified thrombin generation test for the measurement of factor VIII concentrates.

McIntosh JH, Owens D, **Lee CA**, Raut S, Barrowcliffe TW

Journal of Thrombosis and Haemostasis 2003; 1 : 1005-1011

Social adjustment in three cultures : data from families affected by chronic blood disorders. A sibling study.

Clemente C, Tsiantis J, Kolvin I, Ba G, Christogiorgos S, **Lee C**, Taylor B, Miller R.

Haemophilia 2003; 9 : 317-324

Prevalence, causes and characterisation of factor XI inhibitors in patients with inherited factor XI deficiency.

Salomon O, Zivelin A, Livnat T, Dardik R, Loewenthal R, Avishai O, Steinberg DM, Rosove MH, O'Connell N, **Lee CA**, Seligsohn U
Blood 2003; 101 : 4783- 4788

Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion.

CASCADE Collaboration

Acquir Immune Defic Syndr 2003; 34, 1 : 76-83

Biological response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease : results of a multicentre European study.

Federici AB, Mazurier C, Berntorp E, **Lee CA**, Shcarrer I, Goudemand J, Lethagen S, Nitu I , Ludwig G, Hilbert L, Mannucci PM.
Blood 2003 Nov 20

Periarticular aneurysm following total knee replacement in hemophilic arthropathy – A case report.

Mann HA, Goddard NJ, **Lee CA**, Brown SA
J Bone Joint Surg 2003; 85-A(12):2437-40

Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1500 seroconverters.

CASCADE Collaboration

JAIDS Journal of Acquired Immune Deficiency Syndromes 32 : 300-310, 2003

Impact of tuberculosis on HIV disease progression in person with well-documented time of HIV seroconversion.

CASCADE Collaboration

JAIDS 33: 184-190, 2003

- 2004** Short-term risk of AIDS according to count CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era.

CASCADE Collaboration

AIDS 2004; 18: 51-58

The effect of highly active antiretroviral therapy for HIV on anti-HCV specific humoral immune response.

Herrero-Maricnez E, Sabin CA, **Lee CA**, Jones IM, Pillay D, Emery V
J Med Virol 2004; 72 (2):187-93

Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease : results of a multicentre European study

Federici AB, Mazurier C, Berntorp E, **Lee CA** Scharrer I, Goudemand J, Lethagen S, Nitu I, Ludwig G, Hilbert L, Mannucci P
Blood 2004; 103 (6), 2032-8

The impact of HIV on mortality rates in the complete UK haemophilia population

UKHCDO

AIDS 2004, 18:525-533

The response to Desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand's disease.

White B, Lawler P, Nitu-Whalley IC, Riddell A, Hermans C, Brown SA and **Lee CA**.
Brit J Haematol 2004; 126:100-4

Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion : incidence and predictors.

CASCADE Collaboration

AIDS 2004, 18 : 673-681

The use of Levonorgestrel-releasing intrauterine system for the treatment of menorrhagia in women with inherited bleeding disorders.

Kingman CEC, Kadir RA, **Lee CA**, Economides DL
Br J O+G 2004; 111 : 1-4

Prevalence of von Willebrand disease in women with menorrhagia : a systematic review.
Shanker M, Sabin CA, Economides D, Kadir RA
Br J O+G 2004 ; 111 : 734-740

- 2005** Structural interpretation of 39 mutations causing factor XI deficiency using homology modelling
O'Connell NM, Saunders RE, **Lee CA**, Perry DJ, Perkins SJ
J Thromb Haemost 2005; 2, 1-2

A comparison between prophylaxis and on demand treatment for severe haemophilia
Khoriaty R, Taher A, Inati A, **Lee C**
Clin.Lab.Haem 2005;27: 320-323

Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation /removal methods.
Goudemand J, Scharrer I, Berntorp E, **Lee CA**, Borel-Derlou A, Stieltjes N, Caron C, Scherman JM, Bridley F, Tellier Z, Fedrici AB, Mannucci PM.
Journal of Thrombosis and Haemostasis 3: 2219-2227

Detection of known haemophilia B mutations and carrier testing by microarray
Chan K, Sasanakul W, Mellars G, Chuansumrit A, Perry D, **Lee CA**, Wong MS, Chan TK, Chan V.
Thromb Haemost 2005; 94: 872-878

Versatile peptide dendrimers for nucleic acid delivery.
Bayele HK, Sakthivel T, O'Donnell M, Pasi KJ, Wilderspin AF, **Lee CA**, Toth I, Florence AT
Journal of Pharmaceutical Sciences 2005; 94: 446-457

von Willebrand factor : the new treatment paradigm – introduction.
Lee CA, Montgomery RR
Blood Coagulation and Fibrinolysis 2005; 16 (suppl 1) : S1-S2

Twenty five years of HIV infection in haemophilic men in Britain : an observational study.
Sabin CA, Phillips AN, Yee TT, Griffioen A, **Lee CA**
British Medical Journal 2005; 831: 997-8

Factor XI deficiency database : an interactive web database of mutations, phenotypes and structural analysis tools.
Saunders RE, O'Connell NM, **Lee CA**, Perry DJ, Perkins SJ
Human Mutation 2005; 26:192-198

Ortner syndrome and haemophiia
Hermans C, Manocha S, McLaughlin JE, Lipman M, **Lee CA**
Haemophilia 2005; 11: 548-551

Structural interpretation of 42 mutations causing factor XI deficiency using homology modelling
O'Connell NM, Saunders RE, **Lee CA**, Perry DJ, Perkins SJ
J Thromb Haemost 2005; 3 : 127-38

- 2006** Non-invasive first trimester determination of fetal gender: a new approach for prenatal diagnosis of haemophilia.
Chi C, Hyett JA, Flinning KM, **Lee CA**, Kadir RA
BJOG 2006; 113: 239-242

Inhibitor development in haemophiliacs – the roles of genetic vs environmental factors
Lee CA, Lillicrap D, Astermark J
Seminars in Haematology 2006

Current issues facing coagulationists – meeting report
Brown SA, Aledort L, **Lee CA**
Haemophilia 2006;12; 115-123

Disorders of menstruation and their effect on the quality of life in women with congenital factor VII deficiency.
Kulkarni a, **Lee CA**, Griffioen A, and Kadir RA

Haemophilia 2006; 12:248-252

Chi C, Shiltagh N, Kingman CE, Economides DL, **Lee CA**, Kadir RA

Identification and management of women with inherited bleeding disorders: a survey of obstetricians and gynaecologists in the United Kingdom

Haemophilia. 2006 ;12:405-12.

Lee CA, Chi C, Pavord SR, Bolton-Maggs PH, Pollard D, Hinchcliffe-Wood A, Kadir RA.

The obstetric and gynaecological management of women with inherited bleeding disorders - review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization.

Haemophilia 2006;12:301-6

Beeton K, Neal D, **Lee C**.

An exploration of health-related quality of life in adults with haemophilia--a qualitative perspective.

Haemophilia 2005; 11: 123-32

Kulkarni AA, **Lee CA**, Kadir RA

Pregnancy in women with congenital factor VII deficiency

Haemophilia 2006; 12:413-6

Mann HA, Choudary MZ, **Lee CA**, Goddard NJ

Heterotrophic bone formation as a complication of elective joint replacement in haemophilic patients - a case report and literature review.

Haemophilia 2006 12:672-5

Kadir RA, Kingman CE, Chi C, O'Connell NM, Riddell A, **Lee CA**, Economides DL.

Screening for factor XI deficiency amongst pregnant women of Ashkenazi Jewish origin.

Haemophilia 2006;12:625-8.

Sadler JE, Budde u, Eikenboom JCJ, Favaloro EJ, Hill FGH, Holmberg L, Ingerslev J, **Lee CA**, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodieghiero F, Scheppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB.

Update on the pathophysiology and classification of von Willebrand Disease: a report of the subcommittee on von Willebrand factor.

J Thromb Haemost 2006; 4: 2103-14

Lee CA

Pharmacokinetic studies in patients with inherited bleeding disorders – challenges and relevance to clinical practice

Haemophilia 2006; 12:1-2

2007 Lee CA, Aledort LM

Coagulation deficiencies: a look to the future

Haemophilia 2007; 13: 750-7

2008 Lee CA Best practice: protecting research subjects, patients and experimental animals.

Haemophilia 2008; 14: 111

Dunn NF, Miller R, Griffeon A, **Lee CA**

Carrier testing in haemophilia A and B: adult carriers' and their partners' experiences and their views on the testing of young females.

Haemophilia 2008; 14: 584-92

O'Connell NM, Riddell AF, Pascoe G, Perry DJ, **Lee CA**

Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency

Haemophilia 2008; 14: 775-81

Lee CA

Prevention of arthropathy in haemophilia – intensive on-demand treatment. UK perspective.

Haemophilia 2008; 14: Suppl 6 11-5

Rodriguez-Merchan EC, Hedner U, Jimenez-Yuste, **Lee CA**, Morfini M, Querol F, Roosendaal G, Santagostino E, Solimeno LP

Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors.

Haemophilia 2008; 14: Suppl 6: 68-81

2009

Lee CA, Chi C, Shiltagh N, Pollard D, Griffioen A, Dunn N, Kadir RA
Review of a multidisciplinary clinic for women with inherited bleeding disorders
Haemophilia 2009; 15: 359-60

Mann HA, Biring GS, Choudhury MZ, **Lee CA**, Goddard NJ
Ankle arthropathy in the haemophilic patient: a description of a novel ankle arthrodesis technique
Haemophilia 2009; 15: 458-63

Mann HA, Choudhury MZ, Allen DJ, **Lee CA** Goddard NJ
Current approaches to arthropathy of the hip
Haemophilia 2009; 15: 659-64

Lee CA, Aledort LM
Bleeding and clotting: new therapies and old issues revisited.
Haemophilia 2009; 15: 592-6

Chi C, **Lee CA**, England A, Hingorani J, Painsil J, Kadir RA.
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Thromb Haemost 2009; 101: 1104-11

Lee CA
The best of times, the worst of times: a story of Haemophilia.
Clin Med 2009; 9: 453-8

2010 Chi C, Bapir M, **Lee CA**, Kadir RA
Puerperal loss (lochia) in women with or without inherited bleeding disorders
Am J Gynecol 2010; 56: e1-5

Millar CM, Connor N, Dolan G, **Lee CA**, Makris M, Wilde J, Winter M, Ironside JW, Gill N, Hill FG
Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders
Haemophilia 2010; 16: 305-15

Goddard NJ, Mann HA, **Lee CA**
Total knee replacement in patients with end-stage haemophilic arthropathy: 25-year results
J Bone Joint Surg Br 2010; 92: 1085-9

2011 Hedner U, **Lee CA**
First 20 years with recombinant FVIIIa
Haemophilia 2011; 17: e172-82

Zaman SM, Hill Fg, Palmer B, Millar CM, Bone A, Molesworth AM, Connor N, **Lee CA**, Dolan G, Wilde JT, Gill ON, Makris M
The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders known to have received potentially contaminated plasma products
Haemophilia 2011; 17: 931-7

Rodriguez-Merchan EC, Jimenez-Yuste V, Aznar JA, Hedner U, Knobe K, **Lee CA**, Ljung R, Querol F, Santagostino E, Valentino LA, Caffarina A
Joint protection in haemophilia
Haemophilia 2011; Suppl 2 1-23

2012 Kadir RA, Sharief LA, **Lee CA**
Inherited bleeding disorders in older women
Mauritas 2012; 72: 35-41

Peyvandi F, Di Michele D, Bolton-Maggs PH, **Lee CA**, Tripodi A, Srivastava A
 Project on Consensus Definitions in Rare Bleeding Disorders of Factor VIII/Factor IX Scientific and
 Standardisation Committee of the International Society on Thrombosis and Haemostasis.
J Thromb Haemost 2012; 72: 1938-43

- 2013** Kulkarni AA, Osmond M, Bapir M, Riddell A, Smith C, **Lee CA**, Kadir RA
 The effect of labour on the coagulation system in the term neonate
Haemophilia 2013; 19: 533-8

Lee CA

Haemophilia – the first 20years
Haemophilia 2013; 19: 343

Berntorp E, Fuchs B, Makris M, Montgomery R, Flood V, O'Donnell JS, Federici AB, Lillicrap D, James
 P, Budde U, Morfini M, Petrini P, Austin S, Kannicht C, Jimenez-Yuste V, **Lee C**.
 Third Aland Islands conference on von Willebrand disease 26-28 September 2012: meeting report.
Haemophilia 2013; Suppl 3 1-18

BOOKS

- 1986** Blood product therapy in haemophilia - historic papers.
 Editors: **Christine A Lee** and Peter BA Kernoff.
 Science Press, London, 1986, 296 pages.
- 1988** Viral hepatitis - historic papers.
 Editors: **Christine A Lee** and Peter BA Kernoff.
 Science Press, London, 1988, 300 pages.
- 1994** HIV and Haemophilia at the Royal Free.
 Collected Papers 1979 - 1994
 Editor: **CA Lee**.
 Science Press, London, 1994, 168 pages.
- 1996** Baillière's Clinical Haematology - International Practice and Research:Haemophilia.
 Editor: **CA Lee**
 Ballière Tindall, London, June 1996, 178 pages
- 1999** Haemophilia : Recent history of Clinical Management
 Wellcome Witnesses to Twentieth Century Medicine Vol 4
 Editors: Tansey EM, Christie DA
 The Wellcome Trust , Sep 1999, 90 pages
- 2000** Musculoskeletal Aspects of Haemophilia
 Editors: Rodriguez-Merchan EC, Goddard NJ, **Lee CA**

 Blackwell Science Ltd, 2000, 236 pages
- 2002** Inhibitors in patients with haemophilia
 Editors: Rodriguez-Merchan EC, **Lee CA**
 Blackwell Science, 2002, 217 pages

- 2005** Textbook of Hemophilia
Editors: **Lee C.A**, Berntorp E.E, Hoots W.K.
Blackwell Publishing, UK, 400 pages
- 2009** Inherited Bleeding Disorders in Women
Editors: **Lee CA**, Kadir RA, Kouides PBA
Wiley-Blackwell, UK, 192 pages
- 2010** Textbook of Hemophilia, second edition
Editors: **Lee C**, Berntorp E, Hoots K
Wiley-Blackwell, UK, 464 pages
- 2011** Von Willebrand Disease, Basic and Clinical Aspects
Editors: Federici AB, **Lee CA**, Berntorp EE, Lillicrap D, Montgomery R
Wiley-Blackwell, UK, 252 pages
- 2014** Textbook of Hemophilia, third edition
Editors: **Lee C**, Berntorp E, Hoots K
Wiley-Blackwell, UK, 537 pages
- 2019** Inherited Bleeding Disorders in Women, second edition
Editors: Kadir RA, James PD, **Lee CA**
Wiley-Blackwell, UK,

CHAPTERS IN BOOKS

- 1983** **Lee CA**.
'Doctor, I think I'm anaemic'.
In '*Symptomatic Guide to Gastroenterology*'. Editor: Roy Pounder, Smith Kline & French Laboratories Ltd, Welwyn Garden City, 1983: 211-217.
- 1988** **Lee CA**
The clinical aspects of AIDS/HIV.
In: '*AIDS: A Guide to Clinical Counselling*'.
Riva Miller and R Bor. Science Press, London, 1988; 29-34.
- 1989** **Lee CA**, and Kernoff PBA.
Liver disease in haemophilia.
In: '*Factor VIII/von Willebrand Factor, Vol. 2: Clinical Aspects of Deficiency States*'. Editors: Savidge, GF, and Seghatchian MJ, CRC Press, Boca Raton 1989; 255-268.
- 1991** **Lee CA**, Kernoff PBA and Hutton RA.
Haemostasis in liver disease.
In: '*Oxford Textbook of Hepatology*'. Oxford University Press 1991; 25: 1234-1240.
- 1992** **Lee CA**.
Coagulation factor replacement therapy.

In: *Recent Advances in Haematology*, Number 6: Edinburgh
Churchill Livingstone 1992 73-88.

Lee CA

The clinical aspects of AIDS and HIV infection.

In: *AIDS A guide to Clinical Counselling*, Editors: Miller R and Bor R, London, Science Press, London, 1992; 29-4.

Bofill M, Janossy G, Phillips A, Timms A, MacDonald Burns D, Johnson M & **Lee CA**.

Normal control values for CD4 and CD8 T lymphocytes and their relevance for HIV-1 infections.

In: Janossy G et al (Eds): *Immunodeficiency in HIV infection and AIDS*.

Karger, Basel, 1992; 32-45.

Lee CA, Phillips AN, Elford J, Griffiths P, Bofill M, Janossy G & Kernoff PBA.

Applications of CD4 counts in a cohort of HIV-1 positive patients with haemophilia.

In: Janossy G et al (Eds): *Immunodeficiency in HIV infection and AIDS*. Karger, Basel, 1992; 46-54
Basel, Karger, 1992; 46-54.

1993 Lee CA and Dusheiko G.

Hepatitis and Haemophilia.

In: *Viral Hepatitis* Eds : Zuckerman AJ & Thomas HC, Churchill Livingstone, Edinburgh, 1993, pp501-6

Lee CA

HIV and Haemophilia.

In: *ACP Yearbook*, London, 1993, pp 69-71.

1995 Lee CA and Pasi KJ

Haemophilia and von Willebrand's disease In: Pounder R and Hamilton M (Eds) *Handbook of Current Diagnosis and Treatment* Churchill Livingstone, Edinburgh, 1995

Lee CA.

Complications of replacement therapy: transfusion transmitted disease, HIV and hepatitis.

In: C R Rizza and GDO Lowe (Eds) *Haemophilia and its Management* Ballière Tindall, London, 1996

Lee CA

Transfusion transmitted diseases. Chapter 11: 369-394

In: CA Lee (Ed) *Baillière's Clinical Haematology - International Practice and Research: Haemophilia*, June 1996

1996 Lee C

AIDS and the Haemophilic Patient. Chapter 12: 217 - 241

In: *AIDS and Malignancies*. (Eds) Basil C Coleman and Vincent T DeVita Jr.

Lee C

Haemophilia & HIV Infection.

In: *Medicine, Infections* (Ed) Andrew M L Lever & Patrick Sissons

Medicine 1996; 24:9: 149-61

1997 Christine Lee Complications of replacement therapy: transfusion transmitted disease, HIV and

hepatitis. In: *Haemophilia and other inherited bleeding disorders*.

(Eds) CR Rizza & GDO Lowe, WB Saunders Company Ltd. pp 309-364.

1998 Lee CA

Hepatitis and Haemophilia. Chapter 41: 515-526

In: *Viral Hepatitis* (Eds); Zuckerman AJ and Thomas HC, Churchill Livingstone, Edinburgh.

2001 Kadir RA, Lee CA, Economides DL,

Coagulation Defects in Pregnancy.

In: *Contemporary Clinical Gynecology & Obstetrics*. 1:35-48

Lee CA The role of the World Federation of Haemophilia International Haemophilia Training Centres' Committee.

Chapter in: Comprehensive haemophilia care in developing countries (Eds) Sohail MT, Heijnen L
Ferozsons 2001, pp 214-227

- 2004** Laffan M, **Lee CA**
Haemophilia & von Willebrand disease.
Postgraduate Haematology
Eds. Hoffbrand A, Tuddenham E
Blackwell Publishing, UK
- Lee CA**, Kadir R Obstetrics and Gynaecology in Haemophilia
In: Textbook of Haemophilia
Eds . **Lee CA**, Berntorp E, Hoots K
Blackwell Publishing, UK
- Lee CA** Haemophilia & Hepatitis
Viral Hepatitis 3rd Edition
Eds. Thomas HC, Lemon SM, Zuckerman AJ
Blackwell Publishing, UK
- Lee CA**, Montgomery RR
Von Willebrand Factor : the new treatment paradigm – introduction.
Blood Coagulation and Fibrinolysis 2005; 16 (suppl 1): S1-S2

REVIEW ARTICLES

- 1977** **Lee CA**
Haematology: white cell disorders.
General Practitioner, 14 October 1977, 44.
- 1981** **Lee CA**
The blood: treatment of polycythemia.
General Practitioner, 24 April 1981, 33.
- 1982** **Lee CA**
Anaemia: treatment.
General Practitioner, 28 May 1982, 45.
- 1984** **Lee CA** Acquired immunodeficiency syndrome: an update.
Haemofact, 11 May 1984, The Haemophilia Society.
- 1989** **Lee CA**
The natural history of HIV infection.
AIDS Care 1989; 1: 177-179.

- 1990 Lee CA and Kernoff PBA**
Hepatitis and haemophilia.
British Medical Bulletin, 'Viral Hepatitis'.
1990; 46: 408-422.
- Lee CA**
Haemophilia and the hepatitis C virus.
Insight 1990; 1: 4-6.
- Lee CA**
Haemophilia and the hepatitis C virus.
Interferons and Cytokines 1990; 15: 14-16.
- Lee CA**
Natural history of HIV and AIDS.
AIDS Care 1990; 2: 353-357.
- 1991 Lee CA**
Haemophilia and hepatitis past, present and future.
The Haemophilia Bulletin; August 1991.
- Lee CA**
HIV infection in Haemophilia.
Far East Symposium Series.
Excerpta Medica 1991; 44: 1-6.
- 1992 Lee CA**
Progression of HIV disease in a haemophilic cohort followed for eleven years and the effect of treatment.
Haemophilia Society Bulletin 1992; 1: 8-9.
- Lee CA**
Natural History of HIV infection.
Summary from International AIDS Conference 1992
AIDS Care 1992; 4: 449-452.
- 1994 Lee CA** The argument for using high purity factor VIII and IX concentrates in haemophilia. British Blood Transfusion Society; Blood Components Special Interest Group.
Journal of Clinical and Laboratory Haematology 1994; 16: 404-5.
- World Health Organisation Hereditary Disease Programme Division of Non-Communicable Diseases.
Report of a Joint WHO/WFH meeting - The Control of Haemophilia: Modern Treatment of Haemophilia.
Geneva 21-23 March 1994.
- 1995 Lee CA**
Management of patients with HIV and/or hepatitis
Haemophilia 1995; 1 (Suppl 1): 26-34.
- Lee CA**
Hepatitis C and haemophilia (Editorial)
British Medical Journal 1995; 310: 1619-1620.
- Lee CA**
Hepatitis C virus and haemophilia: the natural history of HCV in haemophilic patients.
Haemophilia 1995; 1 (Suppl 4): 8-12.
- 1996 Lee CA**
Commentary: Hope for haemophilic patients with hepatitis
Gut 1996; 39: 887-888
- 1997 Christine Lee, Caroline Sabin, Alexander Miners**
High-cost, low-volume care: the case of haemophilia.
(Editorial) *British Medical Journal* 1997; 315: 962-3

Kinson Z, Dusheiko and **Lee C**.
 GB virus C/hepatitis G virus.
Haemophilia 1997; 3: 235-241

1998 Christine A Lee

The natural history of HIV disease in haemophilia
Blood Reviews 1998;12: 135-144

World Health Organisation Human Genetics Programme Division of Non-Communicable Diseases
Report of a Joint WHO/WFH meeting -The Control of Haemophilia: Haemophilia Care in Developing Countries
 Geneva 16-17 June 1997

Kadir RA, **Lee CA** & Economides DL
 Reproduction and inherited bleeding disorders
Contemporary Reviews in Obstetrics and Gynaecology 1998: 39-46

Kadir R, **Lee CA**, Economides D
 Factor XI deficiency in women
American Journal of Haematology 1999; 60: 48-54

Lee CA,
 Inherited bleeding disorders in obstetrics and gynaecology
British Journal of Obstetrics and Gynaecology 1999, 106: (In Press)

Lee CA
 Hepatitis C and Its Management
 World Federation of Haemophilia Monograph

2001 Lee CA

The management of hepatitis C in haemophilia
CME Bulletin Haematology 2001; 3(3):55-57

Kadir RA, **Lee CA**
 Menorrhagia in adolescents
Paediatric Annals 30:9 541-546

Kadir RA, **Lee CA**, Economides D
 Coagulation defects in pregnancy
Contemporary Clinical Gynaecology & Obstetrics 2001; 1: 35-48

2002 Lee CA

Immune tolerance in haemophilia with factor VIII inhibitors: predictors of success.
The International Monitor 2002; 10 (1) : 22-23

Lee CA
 The evidence behind inhibitor treatment with Porcine Factor VIII
Pathophysiol Haemost Thromb 2002; 32 (suppl 1): 5-8

Miller R, Fields PA, Goldspink G, **Lee CA**, Pasi JK, Perry DJ
 Somatic gene therapy for haemophilia: some counselling issues for today and tomorrow.
Psych Health Med 2002; 7:163-173

Delivery of treatment for haemophilia. Report of a joint WHO/WFH/ISTH meeting
 London UK Feb 2002
 WHO/WFH/ISTH/WG/02.6

2004 Miners AH, Lee CA

Setting research priorities to improve cost-effectiveness estimations of primary prophylaxis with clotting factor for people with severe haemophilia.

Haemophilia 2004 Mar; 10 (Supp 1): 58-62

2005 Yee TT, Lee CA

Transfusion transmitted diseases in haemophilia in developing countries.
Seminars in Thrombosis and Haemostasis 2005, 31: 527-537
 WB Saunders, USA

Lee CA, Abdul-Kadir R

von Willebrand disease and women's health
Seminars in Haematology 2005; 42: 42-48

Federici AB, Berntorp E, Lee CA

The 80th anniversary of von Willebrand's disease: history, management and research.
Haemophilia 2005; 12: 563-572

2012 Lee CA and Gough S

How to write and publish a research paper in *Haemophilia*
 Occasional paper *World Federation Hemophilia*
 2012 No 7

LETTERS

1975 Lee CA and Fielding J.

Combined dietary vitamin B12 deficiency and beta thalassaemia trait.
Lancet 1975; 2: 127-128.

1983 Lee CA, Janossy G, Ashley J and Kernoff PBA.

Plasma fractionation methods and T-cell subsets in haemophilia.
Lancet 1983; ii: 158-159.

1984 Lee CA, Kernoff PBA, Karayiannis P, Waters J and Thomas HC.

Abnormal T lymphocyte subsets in haemophilia: relationship to HLA proteins in plasma products.
New England Journal of Medicine 1984; 310: 1058.

Lee CA, Kernoff PBA, Bofill M, Rizza CR and Downing RG.

- HTLV I and haemophilia
Lancet 1984; i: 1028.
- 1985** Weinbren M, Perinpanayagam RM, Camba L, and **Lee CA**.
Convulsions and encephalopathy in a patient with leukaemia after treatment with metronidazole.
Journal of Clinical Pathology 1985; 9: 1076.
- 1989** Simonds AK, Newman SP, Johnson MA, Talace N, **Lee CA** and Clarke SW.
Aerosolised pentamidine.
Lancet 1989; i: 221-222.
- Webster A, **Lee CA**, Cook DG, Grundy JE, Emery VC, Kernoff PBA and Griffiths PD.
Cytomegalovirus infection and progression to AIDS.
Lancet 1989; ii: 681.
- Lee CA**, Webster A, Griffiths PD and Kernoff PBA.
Symptomless HIV infection after more than 10 years.
Lancet 1989; 335: 425-426.
- 1990** **Lee CA**, Phillips A, Elford J, Janossy G, Griffiths P, Kernoff PBA
10 year follow-up of HIV infection in a haemophilic cohort.
British Journal of Haematology 1990; 75: 623.
- Phillips A., **Lee C.A.**, Elford J., Janossy G. and Kernoff P.B.A.
Monitoring CD4 counts in HIV infection.
Lancet 1990, 337: 1108-9.
- Squire SB, Bagdades EK, **Lee CA**, and Johnson MA
Pneumothorax and aerolised pentamidine prophylaxis.
Lancet 1990; 337: 128-9
- 1991** **Lee CA**, Miller R, Goldman E.
HIV infection in women.
British Medical Journal 1991; 302: 50-51.
- Pereira C, **Lee CA**, Dusheiko G.
Hepatitis C virus
British Medical Journal 1991; 303: 783.
- Lee CA**
Hepatitis C Virus
British Medical Journal 1991; 303: 1330-1331
- 1992** Webster A, **Lee CA**, Black D.
Women in medicine
British Medical Journal 1992; 302: 1406
- Lee CA**.
High purity factor VIII concentrate and HIV infection.
British Medical Journal 1992; 304: 641
- Lee CA**, Chrispeels J, Telfer P, Dusheiko G.
Hepatitis C antibody profile in adults with haemophilia and their sexual partners
Br J Haematol 1992; 81: 134
- Sabin CA, Phillips AN, Elford JE and **Lee CA**.
Progression to AIDS in HIV-infected patients with oral candidiasis or hairy leucoplakia.
AIDS 1992; 6: 750-1
- 1993** Sabin C, **Lee CA** and Phillips AN.
New AIDS definition
Lancet 1993; 341: 178

- Phillips AN, Sabin CA, Bofill M, Janossy G and **Lee CA**.
Are there two types of response to HIV:
Lancet 1993; 341: 1023-1024
- 1994** Phillips AN, Sabin CA, Elford J, Bofill M, Emery V, Griffiths PD, Janossy G and **Lee CA**.
Viral burden in HIV infection.
Nature 1994; 367: 124.
- Collins PW, Jenkins PV, Goldman E, **Lee CA**, Pasi KJP
Intron 22 inversions and haemophilia.
Lancet 1994; 343: 791
- Bolton-Maggs PHB, Colvin BT, Satchi G, **Lee CA**, Lucas GS.
Thrombogenic potential of factor XI concentrate.
Lancet 1994; 344: 748-49
- 1995** Yee TT, **Lee CA**, Pasi KJ
Life-threatening human parvovirus B19 infection in immunocompetent haemophilia.
Lancet 1995; 345: 794-5
- Lee CA**, Sabin CA, Phillips AN, Elford J and Pasi J.
Morbidity and mortality from transfusion-transmitted disease in haemophilia.
Lancet 1995; 345: 1309
- Pasi KJ, Perry DJ and **Lee CA**.
Thromboembolism and the combined oral contraceptive pill
Lancet 1995; 345: 1437
- 1997** **Lee CA**
Investigation of chronic hepatitis C infection in individuals with haemophilia
Br J Haematol 1997; 96: 425-426
- Lee CA** and Sabin CA
The natural history of chronic hepatitis C in haemophiliacs
Br J of Haematol 1997; 96: 872-882
- Yee TT, Amrolia PJ, **Lee CA**, Mir N and Giangrande PL.
Protease inhibitors and unusual bleeding in haemophiliacs.
Haemophilia 1997; 3: 220-221
- Sabin CA, Telfer P, Phillips AN, Bhagani S and **Lee CA**.
Hepatitis C virus infection in a human immunodeficiency virus-positive cohort in Hawaii.
Journal of Infectious Diseases 1997; 176: 542-543 (letter)
- 1998** D Ewart, S Darby, **CA Lee**, PLF Giangrande, RFD Spooner, AN Phillips and CA Ludlam
Immune status in HIV-1 infected men and boys with haemophilia in the United Kingdom.
AIDS 1998; 12: 956-958
- Effect of coinfection with hepatitis G virus on HIV disease progression in hemophilic men.
Sabin CA, Devereux H, Kinson Z, Griffioen A, Brown D, Dusheiko G and **Lee CA**.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998; 19: 546-549
- 1999** Is a change of Factor VIII product a risk factor for the development of a factor VIII inhibitor?
Yee TT & **Lee CA**
Thromb Haemost 1999; 81: 852
- Family issues in HIV infected haemophilic patients
Yee TT, Goldman E, Devereux H, Sabin C and **Lee CA**
AIDS 1999; 13: 2314-5
- 2000** Prevalence of clotting factor deficiencies in a large population with von Willebrand disease.
Nitu-Whalley IC, Hermans C and **Lee CA**

Thromb Haemost 2000; 84: 514-5

Oral immune tolerance induction to factor VIII via breast milk, a possibility?

Yee TT and **Lee CA**.

Haemophilia 2000; 6:591

Reassessment of the correlation between the von Willebrand factor activity, the PFA-100, and the bleeding time in patients with von Willebrand disease.

Lee C A, Ionna Nitu-Whalley, Hermans C

Thromb Haemost 2001; 86:715-6

2002 Single-dose pharmacokinetics of porcine Factor VIII (Hyate-C).

Hermans C, Owens D, Longo G, Morfini M, **Lee CA**.

Thromb Haemostas 2002; 87:352-353

AIDS, hepatitis and haemophilia in the 1980's : memoirs of an insider.

Lee CA

J Thromb Haemost 2003; 1:

POSTGRADUATE STUDENTS SUPERVISED

Dr Seng Lim 1988 – 1991	<i>'Gastrointestinal effects of HIV disease'.</i> MD Monash University, Australia.
Dr Paul Telfer 1991 – 1994	<i>'HCV infection in haemophilia patients'</i> DM, University of Oxford.
Dr Caroline A Sabin 1991 – 1995	<i>'Follow up of a cohort of anti-HIV seropositive haemophiliacs for up to 15 years from seroconversion.'</i> PhD, University of London.
Dr Helen L Devereux 1992 – 1996	<i>'The molecular biology of HCV infection in haemophilia'.</i> PhD, University of London.
Dr Dale Owens 1992 – 1997	<i>'The coagulation disorder associated with snake bite'.</i> PhD, University of London
Dr Ricarda Steinbrecher 1992 – 1994	<i>'Study of myosin heavy chain genes in mammalian muscle and the characteristics of the different isoform genes and their regulation during development'.</i> PhD, University of London.
Dr Jo Kennelly 1993 – 1994	Postdoctoral Student (PhD University of Cambridge) A report, commissioned by the Department of Health, has been prepared: <i>'Costs of treating haemophilic patients with HIV infection'.</i>
Dr Gaynor Miller 1993 – 1997	<i>'To construct genes using muscle promoters and signal sequences for the purposes of gene therapy using muscle as the in vivo expression system'.</i> PhD, University of London.
Dr Alexander Miners 1995 – 1998	<i>'The economics of haemophilia care'.</i> PhD, University of London.
Dr Rezan Kadir 1995 – 1998	<i>'Obstetrics and gynaecological problem in patients with disorders of haemostasis'.</i> MD, University of London.
Dr Ioana Nitu 1998-2001	<i>'The diagnosis, natural history and treatment of von Willebrand's disease'</i> MD, University of London
Dr Thynn Thynn Yee 1998 – 2001	<i>'The side effects of therapy for haemophilic patients'</i> MD, University of London
Dr Esteban Herrero 1998-2001	<i>'The molecular basis of HIV and HCV interactions in haemophilia'</i> PhD, University of London
Ms Jenny McIntosh 2000 – 2004	<i>'A study of the haemostatic effectiveness of FVIII concentrates'</i> PhD University of London
Dr Karen Beeton 2003 – 2006	<i>'Quality of Life in Haemophilia'</i> PhD University of Hertfordshire
Dr Niamh O'Connell 2001 – 2009	<i>'Factor XI deficiency : A comprehensive study of genetic mutations, protein structural abnormalities and clinical phenotype'.</i> PhD University of London
Mr Haroon Mann 2005- 2009	<i>'Orthopaedic surgery in patients with Haemophilia'</i> MD University of London
Dr Claudia Chi 2005 – 2009	<i>'Antenatal diagnosis in women with inherited bleeding disorders.'</i> MD University of London
Dr Ashwini Kulkarni	<i>'The obstetrics and gynaecology of women with inherited bleeding disorders'</i> MD University of London

LECTURES - 1994 to present

1994	5th - 6th January	Delhi, India Two lectures: World Federation of Hemophilia and WHO workshop on haemophilia and HIV.
	12th March	London, UK <i>Hepatitis & Haemophilia</i> : Haemophilia Society
	21st - 23rd March	Geneva, Switzerland Participant - Workshop on Haemophilia Care WHO and World Federation of Hemophilia
	23rd - 29th April	Mexico City Five lectures and Chair of symposium World Federation of Hemophilia bi-annual meeting
	13th May	Dublin, Ireland Presentation: <i>Recombinant FVIII</i> : Department of Health
	16th May	London, UK <i>Natural history HIV in haemophilia</i> : Guy's Hospital
	26th - 27th May	Cambridge, UK Rapporteur : European Meeting on self-sufficiency
	21st June	Windsor, UK Organiser, Chair and one lecture at Scientific Meeting on Recombinant Factor VIII
	14th September	Southampton, UK Lecture: British Blood Transfusion Society
	22nd September	London, UK Lecture: British Blood Transfusion Society, Colindale Blood Component Special Interest Group
	24th September	Santorini, Greece <i>Recombinant Factor VIII</i> : Haemophilia Federation of Greece
	4th October	London, UK <i>High Purity Factor IX</i> : National Scientific Meeting
	21st October	Milan, Italy Lecture: European Haematological Association
	27th - 28th October	Jakarta, Indonesia Two lectures: World Federation of Hemophilia Workshop
	11th November	Cap d'Antibes France Lecture: International Meeting on Recombinant Factor VIII
	17th November	London, UK <i>Recombinant Factor VIII</i> : Royal London NHS Trust, Department of Haematology
	11th December	London, UK Organiser, Chair and one lecture at international symposium on 'Hepatitis C': Royal Free Hospital & School of Medicine
	16th December	London, UK

Transfusion transmitted disease & haemophilia: Diploma of Clinical Haematology Course. Royal Postgraduate Medical School,

1995	26th - 30th January	Delhi and Poona, India Organiser, four lectures, Chair of sessions at two workshops : World Federation of Hemophilia and Haemophilia Federation of India
	4th April	Brighton, UK Chair of Session: British Society of Haematology
	5th May	Manchester, UK Lecture : HIV infection in haemophilia
	1st June	London, UK Lecture: Immunology Department, University College London Medical School
	10th June	Jerusalem, Israel Lecture: Standardisation Sub-committee of International Society of Thrombosis and Haemostasis
	18th August	London, UK Lecture: AIDS Oncology Group, University College Hospital
	9th October	London, UK Lecture: King's College Hospital, Department of Haematology
	20th October	Killievelyn, Northern Ireland Lecture: Irish Haemophilia Society
	13th November	Seville, Spain Lecture: Spanish Federation of Haemophilia
	11th December	London, UK Organiser and Chair of International meeting on Factor XI deficiency : Royal Free Hospital and School of Medicine
1996	13th March	Kingston, UK Lecture: Kingston University
	29th February - 1st March	Bermuda Chair : WHO/WFH International Conference
	20th - 21st March	Johannesburg, South Africa Three lectures: World Federation of Hemophilia Workshop
	12th April	Newcastle-upon-Tyne, UK Lecture: Medical Department. Newcastle General Hospital
	17th May	Bari, Italy Lecture: Italian Haemophilia Directors
	23rd - 28th June	Dublin, Ireland Chair of three symposium and one lecture : World Federation of Hemophilia Bi-annual meeting
	12th September	London , UK <i>Hepatitis in Haemophilia</i> : Royal College of Physicians
	18/19th September	Tehran, Iran Four lectures: Iranian Blood Transfusion Society
	27th September	Belfast, Ireland Lecture: Irish Blood Club

16th December	London, UK Royal Postgraduate Medical School <i>HIV & HCV in Haemophilia</i> : DCP: Haematology course
1997 January	London, UK <i>Recombinant Clotting Factors</i> : Talk to the Haemostasis Club
25th/26th January	Dublin & Cork, Ireland <i>Women and Bleeding Disorders</i> : Haemophilia Society of Ireland
1st February	Queenstown, New Zealand <i>Economics of haemophilia treatment</i> :Haemophilia Directors of New Zealand and Australia
15/16th February	Jerusalem, Israel Presentations : Organising Committee World Federation of Haemophilia Meeting 1998
5th March	Pasadena, USA Chair : Haemophilia Treatment with Recombinant Factor VIII
19th March	London, UK Case presentation: Staff Round, Royal Free Hospital
16th April	London, UK Presentation : Vaccine Consensus Meeting for hepatitis A and B Royal Society of Medicine
5 - 7 May	Ankara, Turkey Invited speaker - three lectures: First National Haemophilia Meeting
21st May	London, UK Case Presentation : Grand Round, Royal Free Hampstead NHS Trust
5th/6th June	Florence, Italy Lectures : Factor VIII/Factor IX Committee; Meeting on Factor VIII Pharmacokinetics, XVth Congress ISTH, Florence
16th/17th June	Geneva, Switzerland Lectures : WFH/WHO Meeting 'Delivery of Haemophilia Care in the Developing World'
18th June	London, UK <i>Women and Bleeding Disorders</i> : BBC Radio interview 'Medicine Now'.
25th June	London, UK <i>Factor XI to patients with factor XI deficiency</i> : Royal Free Hampstead NHS Trust
29th July	Warwick, UK <i>Pharmacokinetics of Recombinate</i> : Pharmacokinetics : Baxter investigators meeting.
11th September	Cambridge, UK <i>Treatment of HIV Infection</i> : Invited speaker, UKHCDO annual scientific meeting.
18th/19th/20th September	Taiwan, Indonesia Three lectures in three cities : National Haemophilia Organisation
1st October	Frankfurt, Germany <i>The Management of Rare Bleeding Disorders</i> : Invited speaker - European Blood Transfusion Society.

	22nd October	London, UK Case presentation : Grand Round, University College Hospital
	10th November	London, UK Chair and lecture <i>Transfusion Transmitted Hepatitis C Infection</i> : Royal Free Hampstead NHS Trust
	4th December	San Diego, USA Chair / lecture / poster: ASH meeting - Hepatitis C and Haemophilia Lecture: <i>Pharmacokinetics of Porcine Factor VIII</i> . Poster : <i>Pharmacokinetics of Recombinant Factor VIII</i> .
1998	10th February	London, UK Chair of the Wellcome Witness Seminar on Haemophilia
	3rd March	Puerto Rico, South America Lecture : Haemophilia and the Developing World, Workshop - WHO
	20th April	Los Angeles, USA <i>New Variant CJD</i> : 'Recombinant' Investigators Meeting
	18th May	The Hague, The Netherlands <i>World Federation of Haemophilia Global Haemophilia Care</i> : World Federation of Haemophilia 23rd Congress
	3rd June	London, UK <i>The Economics of Haemophilia Care</i> : Katharine Dormandy Trust patients' meeting
	19th June	London, UK <i>HIV and Haemophilia</i> : Meeting in Honour of Professor Roger Hardisty. Royal Free Hampstead NHS Trust
	8th July	Amsterdam, The Netherlands <i>The Safety of Plasma-derived Clotting Factor Concentrates</i> : Meet the Expert at European Society of Haematology.
	24th September	Sweden <i>Von Willebrand's Disease and Women</i> : Meeting of Nordic Haemophilia Treaters in the Aland Islands
	26-30th October	Pakistan, India Two lectures : <i>HIV and Hepatitis C</i> and <i>Genetic Counselling and Haemophilia</i> . World. Federation of Haemophilia Training Workshop.
	4th December	USA Three lectures : <i>Women and Bleeding Disorders / Menstrual Issues / Women and Bleeding Disorders: Pregnancy and Delivery</i> . American Society of Haematology Symposium on 'Haematology and Women's Health'.
1999	July	London UK. Invited speaker: <i>Surveillance of HIV and HCV in haemophilia</i> : UKXIRA International Workshop on Infection Surveillance post Xenotransplantation
		London UK <i>A Clotting Bleeder</i> : Case presentation, Royal Free and University College Medical School Grand Rounds
	August	Washington, USA <i>Recombinant Clotting Factors in the Treatment of Haemophilia</i> : International Society for Thrombosis and Haemostasis, Invited Speaker.

	October	Stockholm , Sweden <i>Women and Bleeding Disorders</i> : Arosenius Lecture Ivan Arosenius Symposium.
	November	Iran <i>HCV in Haemophilia</i> : IHTC Workshop for WFH,
	Nov - Dec	Melbourne, Australia <i>HCV / HIV / Treatment of Haemophilia / Women and Bleeding Disorders</i> : Alfred Whole Time Medical Specialist Visiting Professorship
2000	February	Houston, USA <i>Women and bleeding disorders</i> : Visiting Lecturer University of Texas
	March	Bournemouth, UK <i>Women and bleeding disorders</i> : BSH
	June	Taipei, Indonesia Presentation, SSC of ISTH Maastricht 2000 First International Asian-Pacific Conference on Thrombosis and Haemostasis.
	July	Montreal, Canada Four oral presentations ; World Federation of Haemophilia, XXIV International Congress
	October	London, UK <i>Inhibitors – an overview</i> Medicine for Managers Pan Thames Haemophilia Consortium London ,UK <i>The natural history of HIV and HCV in the Royal Free Haemophilia Cohort</i> Virology Seminar Royal Free and UC Medical School Helsinki, Finland <i>Bleeding in Women and von Willebrand's Disease</i> Nordic Haemophilia Meeting.
	November	Hong Kong <i>Providing a haemophilia service</i> Transfusion transmitted disease Hong Kong/WFH/KDTrust /University of Hong Kong Workshop Manila, Philippines <i>Women and bleeding</i> Symposium for opening of haemophilia ward, Hospital of St Tomas
2001	January	London, UK <i>Management of Factor XI deficiency</i> 3 rd Haemophilia London Workshop, Goring Hotel.
	February	London, UK <i>Gynaecological Problems in Women with Bleeding Disorders</i> Royal College of Obstetrics & Gynaecology.
	March	London, UK <i>Genetics and its place in haemophilia care in 2000</i> Royal Free Hampstead NHS Trust
	May	London, UK <i>Recombinant PFM</i>

3rd Hyland Immuno Haemophilia Symposium.

Santa Monica, USA

Ethics in Publication :

XIth Hyland Immuno Study Update.

London, UK

Natural History of HCV in Haemophilia

HIV & HCV co-infection.

Haemophilia Society Meeting.

June

Baltimore, USA

Women and von Willebrand Disease

Clyde B McAuley Award.

London, UK

Studies on Recombinant Products

ISTH/FDA/NIBSC/EP Workshop on FVIII Standardisation.

Royal College of Physicians.

October

Bath , UK

Prevalence study in UK haemophiliacs (vCJD)

UKHCDO/BSTH

November

Dublin, Ireland

Porcine Factor VIII

Evidence Based Haemostasis

December

London, UK

Management of inherited bleeding disorders in pregnancy

Imperial College London

2002 February

Birmingham, UK

vWD in bleeding women

National meeting, von Willebrand Disease : Current dilemmas & treatment

May

Seville, Spain

Two lectures - *The natural history of hepatitis in haemophilia / DDAVP*

Treatment of vWD patients :

World Federation of Haemophilia XXV International Congress

November

Orlando, USA

The Hidden Factor : Issues and Options for Women who are Carriers

National Haemophilia Federation

London, RC Path

Care of patients with haemostatic disorders – Identifying the risks and maximising the benefits.

Laboratory monitoring of treatment and response.

2003 March

Budapest

Why do our patients bleed?

Insights into Haemophilia : Addressing the Challenges

Wyeth Pharmaceuticals

Seefeld, Austria

Treatment options of haemophilia in the 21st Century

National meeting of the German Haemophilia Treaters

Biotest pharmaceuticals

May

Montreal, Canada

Management of VWD in women

First Canadian State of the Art Conference on VWD

		Canadian Haemophilia Society
	June	ISTH Birmingham <i>Management of FVII and FXI deficiency with rFVIIa</i> Novo Nordisk symposium
	September	Beirut, Lebanon <i>Treatment options for haemophilia</i> <i>Complications of haemophilia</i> Lebanese Haemophilia Society
	October	Surfers Paradise, Australia <i>Von Willebrand Disease</i> <i>Diagnosis of von Willebrand disease</i> <i>Bleeding disorders in women</i> Haemophilia Federation of Australia
	November	Tullemore, Ireland <i>Von Willebrand disease</i> Haemophilia Association of Ireland (HAI)
2004	May	Tallin, Estonia <i>von Willebrand disease and women</i> 4 th Baltic Conference of Haematology
	June	Venice, Italy <i>VWF assays in diagnosis of VWD</i> SSC of ISTH
	June	Ljubljana, Slovenia <i>The future of treatment for haemophilia and von Willebrand disease 18th</i> <i>International Congress on Thrombosis</i> 18 th International Congress of Thrombosis
	September	Malmo Sweden The history of haemophilia International course on haemophilia
2005	January	Puerto Rico The basis of inhibitor development Annual hemophilia research study update
	February	Budapest, Hungary Women with bleeding disorders and obstetrics International symposium – Women's health issues in thrombosis and haemostasis
	March	Cairo, Egypt Inherited bleeding disorders and adolescent girls Egyptian Society of paediatric Haematology and Oncology (ESPHO)
	October	Malmo, Sweden The history of haemophilia International course on haemophilia.
	October	European Medicines Agency, London, UK Epidemiological data for sporadic CJD and plasma-derived medicinal products – including information on current studies for spCJD and vCJD. Expert workshop on plasma-derived and other medicinal products and vCJD risk.
	November	Cambridge, UK Women and inherited bleeding disorders Department of Haematology

2006	April	Oxford, UK The best of times, the worst of times - a story of Haemophilia Oxford Alumni, University of Oxford Medical School
	May	Gloucester BMA, UK The best of times, the worst of times – a story of haemophilia
	July	Oslo, Norway Assays for VWD FVIII and FIX subcommittee of SSC ISTH
	Nov	Leeds, UK Tribute to Peter Kernoff Annual Scientific meeting UKHCDO
	Nov	London, UK The best of times, the worst of times – a story of haemophilia. Hampstead Medical Society
2007	March	Montreal, Canada Quality of Life and Global Perspective of Women and Bleeding Disorders Symposium to celebrate 100 years of Sainte Justine Hospital
	May	Parma, Italy Building registries and networks for Haemophilia Care, a national approach: United Kingdom XXth European Haemophilia Conference
	July	Geneva, Switzerland International Society on Thrombosis and Haemostasis Management and prevention of recurrent haemarthrosis in haemophilia patients
2008	March	Madrid, Spain Prevention of arthropathy in haemophilia: Intensive on demand treatment, UK perspective Panel of Experts meeting
	March	Royal College of Physicians Fitzpatrick Lecture The Best of Times, the Worst of Times, a story of Haemophilia
	October	Malmö, Sweden International Course in Haemophilia A history of Haemophilia How to Publish a Paper
	November	Melbourne, Australia – the women's Victoria Inherited Bleeding Disorders in Women
	November	Guy's and St Thomas', London A Multidisciplinary Forum Obstetric and Gynaecological Management of Women with Inherited Bleeding Disorders – A Haematologist's Viewpoint
	November	Belfast, Northern Ireland Bradford, Yorkshire Multidisciplinary workshops 'Who claims Menorrhagia'

2009	May	Antalya, Turkey National Haemophilia Congress Women with Inherited Bleeding Disorders
	November	Royal Society of Medicine A Multidisciplinary Forum – Working Together to Improve Women's Health 2009: Focus on Bleeding Disorders Von Willebrand's Disease: The Burden in Women
	November	London, UK International Round Table on Von Willebrand's Disease – Acute Menorrhagia How should acute menorrhagia be evaluated in terms of laboratory testing
2010	April	Malmö, Sweden Von Willebrand Disease – from theory to clinical practice Gynaecological Aspects of Von Willebrand Disease
2014	April	Malmö, Sweden Von Willebrand Disease – from theory to clinical practice Gynaecological Aspects of Von Willebrand Disease
2014	October	Malmö, Sweden A History of Haemophilia
2015	April	Malmö, Sweden Von Willebrand Disease – from theory to clinical practice Gynaecological Aspects of Von Willebrand Disease